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 I 
Abstract  
Background: Magnesium (Mg) based metals have been applied in orthopaedic and cardiovascular (as 
stent) applications due to (e.g.) their excellent biodegradability and tissue regeneration abilities. 
Endothelial cells (ECs) and mesenchymal stem cells (MSCs) represent two protagonists of 
angiogenesis and osteogenesis. The responding of angiogenesis and the EC-MSC communication to 
Mg degradation products and oxygen content are vital to vascular remodelling and later fracture 
regeneration. Methods: Firstly, human primary ECs were exposed to various concentrations of 
extracellular Mg degradation products (control (0.8 mM - cell culture media), 2, 4, and 8 mM) under 
either hypoxia (5% O2) or normoxia (20% O2). Furthermore, in order to understand the influences of Mg 
degradation and oxygen conditions on the ECs-MSCs communication, a non-contacting (or transwell 
system) and a contacting cell culture models were established. With these models, the various stages 
of fracture healing could be mimicked: angiogenesis, MSCs attraction / migration and tissue modelling. 
In the monoculture, cell metabolism and proliferation, as well as wound healing and tube formation 
assays (reflecting two different stages of angiogenesis: migration and tube formation) were studied. In 
coculture, cells proliferation and ratio were measured by deoxyribonucleic acid (DNA) content and flow 
cytometry, respectively. Additionally, MSCs migration was assessed by wound healing assay. Gene 
regulation in monoculture and different coculture were investigated by semi-quantitative real time 
polymerase chain reaction (qRT-PCR). Furthermore, several angiogenic factors, such as vascular 
endothelial growth factor A (VEGFA) were also quantified. Results: Increased proliferation and reduced 
metabolism of ECs were measured with Mg extracts under hypoxia but not under normoxia. Under 
normoxia and with Mg extracts, ECs migration exhibited a bell-shaped curve. The same pattern was 
observed with vascular endothelial growth factors (VEGFs) expression. Under normoxia and with Mg 
extracts but not hypoxia, ECs tube formation was decreased. The regulation of selected genes during 
angiogenesis under the influence of Mg degradation products and O2 contents were also investigated 
and different expression profiles were found between the migration and tube formation stage. In 
coculture systems, Mg decreased the proliferation of MSCs in transwell under hypoxia while an 
increased ratio MSCs/ECs in direct-contact coculture was measured as well as a more obvious 
decreased proliferation of ECs. MSCs migration was increased by magnesium extracts only under 
hypoxia. Expression of selected genes like factors related to extracellular matrix, hypoxia inducible 
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factors and other angiogenetic regulators was obviously influenced by Mg and hypoxia. In transwell, 
hypoxia decreased the effect of Mg on cytokines levels (e.g., migratory factors and other regulators like 
VEGFA). However, these cytokines as well as mineralisation were remarkably increased with Mg 
degradation products under heterotypic contact and hypoxia conditions. Conclusion: These results 
suggest that Mg extracts did not interfere with angiogenesis under hypoxia. Furthermore, Mg, hypoxia, 
and heterotypic contact were beneficial to stromal ECs and MSCs, providing a suitable niche 
environment and highlighting the application of Mg in regenerative medicine. 
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Zusammenfassung 
Der Hintergrund: Biologisch abbaubare Magnesium (Mg) – basierte Legierungen  wurden aufgrund 
ihrer hervorragenden biologischen Eigenschaften wie Abbaubarkeit und an die Geweberegeneration in 
der Orthopädie und Gefäßchirurgie in Form von Stents eingesetzt. Endothelzellen (ECs) und 
mesenchymale Stammzellen (MSCs) repräsentieren zwei Protagonisten der Angiogenese und 
Osteogenese. Die Reaktion der Angiogenese und die EC-MSC-Kommunikation auf eine Mg2+ 
Supplementation und einen verminderten Sauerstoffgehalt ist für die vaskuläre Remodelierung und die 
spätere Frakturheilung von entscheidender Bedeutung. Die Methoden: Humane primäre ECs wurden 
verschiedenen Konzentrationen extrazellulärer Mg Degradationsprodukte entweder unter Hypoxie oder 
Normoxie ausgesetzt. Um die EC-MSC-Kommunikation beim Abbau des Mg und unter veränderten 
Sauerstoffkonditionen zu verstehen, wurden ein kontaktfreies (Transwell-System) und ein 
Zellkulturmodell, das einen direkten Kontaktierung ermöglicht, etabliert. Somit können die 
verschiedenen Stadien der Frakturheilung nachgeahmt werden. Diese sind: Angiogenese, Anziehung / 
Migration von MSC und Gewebemodellierung. In Kokultursystemen wurden die Zellproliferation und das 
Zahlenverhältnis durch DNA-Gehalt bzw. Durchflusszytometrie gemessen. Darüber hinaus wurde die 
MSC-Migration, die durch einen Wundheilungsassay beobachtet wurde. Die Genregulation der ECs-
Monokultur und verschiedener Kokulturen wurde mittels qRT-PCR untersucht. Die Ergebnisse: 
Erhöhte Proliferation und reduzierter Metabolismus der ECs wurden mit Mg-Extrakten unter Hypoxie 
gemessen, nicht jedoch unter Normoxie. Unter Normoxie und mit Mg-Extrakten zeigte die EC-Migration 
eine glockenförmige Kurve. Unter Normoxie und mit Mg-Extrakten war die Bildung von EC-Röhrchen 
verringert, nicht jedoch unter Hypoxie. Dasselbe Muster wurde bei der Expression vaskulärer 
Endothelialwachstumsfaktoren (VEGFs) beobachtet. Die Regulierung ausgewählter Gene während der 
Angiogenese, beeinflusst durch Mg-Abbauprodukte und O2-Gehalte, wurde ebenfalls untersucht und es 
wurde ein offensichtlich unterschiedliches Expressionsprofil zwischen dem Migrations- und dem 
Stadium der Kapillaren Bildung gefunden. In Kokultursystemen reduzierte Mg die Proliferation von 
MSCs in Transwells unter Hypoxie, erhöhte jedoch das Verhältnis von HUCPV / HUVEC in direkten 
Kontaktkulturen und verringerte die Proliferation von ECs. Eine verringerte Proliferation von ECs war 
bei der direkten Kontaktkultivierung offensichtlicher. Die MSC-Migration wurde nur unter Hypoxie durch 
Mg-Extrakten erhöht. Die durch Mg induzierte Genregulation wurde unter hypoxischen Bedingungen 
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verändert, wie Faktoren, die mit extrazellulärer Matrix, Hypoxie-induzierbaren Faktoren und anderen 
angiogenetischen Regulatoren zusammenhängen, anzeigen. Im Transwell-System verringerte Hypoxie 
die Wirkung von Mg auf den Zytokinspiegel von Migrationsfaktoren und anderen Regulatoren wie 
VEGFA. Diese Zytokine und die Mineralisierung waren jedoch mit Mg-Abbauprodukten unter 
heterotypischen Kontakt- und Hypoxiebedingungen signifikant erhöht. Das Fazit: Diese Ergebnisse 
legen nahe, dass Mg-Abbauprodukte die Angiogenese unter Hypoxie nicht negativ beeinflussen. Die 
positiven Eigenschaften von Mg, Hypoxie und heterotypischen Kontakt auf den stromalen ECs und 
MSCs stellen eine geeignete Nische Umgebung dar und zeigen eine mögliche Anwendung von Mg in 
der regenerativen Medizin. 
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Introduction 
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1 Introduction 
In the arena of public health, disability and chronic disease are worldwide problems that influence 
independence in community life, work absenteeism, and physical activity levels. Population ageing is 
expected to rapidly rise during the next decades, and older populations tend to be more disturbed by 
chronic diseases. Lasting cures for chronic diseases always carry high medical costs and long-term 
disabilities. Approximately 86% of annual health care expenditures in the USA involve chronic diseases1. 
Osteoporosis (OP) causes more than 8.9 million fractures annually and results worldwide in an 
osteoporotic fracture every 3 seconds2,3. Blood vessel formation (angiogenesis) is an important element 
that accompanies fracture healing (osteogenesis) and influences eventual clinical outcomes. 
Additionally, angiogenesis dysfunction also plays vital roles in cardiovascular disease, which is the 
leading cause of death worldwide4. 
To cope with these issues, intervention is widely applied to prevent dysfunctional angiogenesis. In the 
field of regenerative medicine, fixation implants and tissue regeneration have been developed to support 
healing after bone diseases and fractures. Because of their material properties and biocompatibility, 
magnesium (Mg)-based materials have been developing into promising implants for bone fixation and 
recovery. The mechanism still requires investigation into the interactive context of bone implantation due 
to the complex hierarchical structure of bones. 
Thus, the present study concentrates on the roles of mesenchymal stem cells (MSCs) and endothelial 
cells (ECs), which are two important local stromal cells involved in hypoxia during bone healing. The 
role of the endothelial cell, as the protagonist of blood vessel formation, in capillary formation is 
investigated under the influence of Mg-containing degradation products and hypoxia. Furthermore, gene 
regulation, metabolism and VEGF secretion, when mediated by Mg and hypoxia, are investigated. 
Cytokine secretion, the gene regulation of MSCs-ECs, the migration of MSCs and the eventual fate of 
MSCs are investigated when interacting with ECs, environmental hypoxia and Mg-containing 
degradation products.
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2 State of the art 
2.1 Magnesium in biology 
Metal ions are normally obtained within the food chain across the ecosystem. Magnesium is the 
fourth most abundant essential element of vertebrate animals and the second most abundant 
intracellular cation after potassium (K). An adult human body contains a total of ~24 g of Mg, which is 
naturally introduced into the body via dietary intake5.  
Mg is unequally circulated within organisms and tissues in the form of salts (e.g., MgCl2 and MgSO4). 
The balance between intestinal absorption and renal excretion regulates Mg2+ homeostasis, as indicated 
in Fig. 1. Almost 52.9% of the Mg in vivo is located in bones, and only 0.8% is found in the blood. Mg in 
the human body is categorised into ionised, complexed and protein-bound states, with ionised Mg 
having the greatest biological activity. Mg homeostasis is maintained by absorption through the gut, 
bone and kidney. In the gut, Mg is absorbed mainly in the small intestine by a passive and paracellular 
mechanism, which is driven by an electrochemical gradient and solvent drag6. A minor but important Mg 
fraction is transported via the transcellular transporter transient receptor potential melastatin 6 and 7 
(TRPM6/7)7. Then, Mg ions are stored in bone mineral, with 1/3 of skeletal Mg remaining on either the 
cortical bone or hydroxyapatite surface, or in the hydration shell around the crystal8. Such bone surface 
Mg can act as a reservoir and exchange correspondingly with Mg loading from serum and the 
physiological extracellular environment6,9. Eventually, excess Mg is excreted via the kidney and the 
faeces (Fig. 1).  
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Fig. 1 Magnesium distribution and homeostasis in the body. Bones and muscles are the most important 
reserves of Mg, one-third of which is exchangeable between the reservoir and blood serum to maintain 
the extracellular homeostasis.  
Extensive clinical observation and epidemiological investigation have raised awareness of the clinical 
association between disease and Mg status (Table 1). Even short disturbances in Mg homeostasis have 
induced cellular events10, and the health risk induced by Mg deficiency should be considered. Various 
bone symptoms are reported to correlate with Mg status in both genders and at different ages11. Lower 
concentrations of serum magnesium lead to hypomagnesaemia, which is widely reported as an essential 
hospitalisation status and can result in various pathological consequences5, such as cardiovascular 
diseases12, diabetes13 and osteoporosis9. The pathological research suggests roles for Mg in 
osteoporosis (OP) that involve an influence on cytokine secretion, inflammation activation, osteoclast 
formation and osteoblast inhibition9 Accordingly, Mg supplementation is implicated in the stimulation of 
bone regeneration by reversing inflammation cascades, such as by decreasing the cytokine profile into 
an anti-inflammatory one in the clinic14. Mg disorder also depends on an altered absorption of other 
metal ions on the cell membrane and numerous biochemical reactions. For example, Ca help with the 
hydrolysis of adenosine triphosphate (ATP)15. Due to similar chemical features, Mg often acts as a non-
competitive antagonist to metal ions6. For instance, Mg and Ca absorption both occur via TRPM6 and 
TRPM7 transport in the intestine7. Mg can occupy voltage-dependent Na+-Ca2+ channels16,17 and the N-
methyl-D-aspartate receptor (NMDAR) regulating the Na+-Ca2+-K+ pump16,17. The non-competitive 
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antagonism by Mg is determined by its hydration shell, which cannot be easily stripped off to allow 
passage through the narrow channels on cell membranes6.  
Table 1 Diseases and factors related to magnesium deficiency and supplementation 
2.2 Mg-based biodegradable implants 
To heal fractures, cure soft-tissue injuries and reconstruct tissue, orthopaedic applications presently use 
various materials such as polymers (e.g., polylactic acid or PLA), titanium and cobalt-chrome alloys, 
ceramics and composites (e.g., PLA/hydroxyapatite (HA) and carbon fibre composites). Such fixation 
devices provide stability and maintain the alignment of bone fragments (Table 2) in an external or 
intramedullary location18. However, such devices can induce side effects. For instance, (D, L-Lactide) 
Mg treatment Disease Influenced molecule/parameter 
Magnesium 
deficiency 
Osteoarthritis 
(OA); 
Joint space 
narrowing (JSN); 
Osteoporosis 
(OP) 
tumour necrosis factor α (TNF-α); substance P (SP); parathyroid 
hormone (PTH); 1, 25-dihydroxyvitamin D (VD3); N-methyl-D-
aspartate (NMDA) receptor; interleukin-1β (IL1β); nuclear factor-κB 
ligand (NF-κB); C-reactive protein (CRP); bone mineral density (BMD) 
Inflammation 
blood pressure; fibrinogen; plasma albumin; IL6; 
lysophosphatidylcholine (LPC); thiobarbituric acid reactive substances 
(TBARS); vitamin E; free radicals; granulocyte colony-stimulating 
factor receptor (G-CSF-R); chemokine (C-C motif) ligand 4 (CCL4); 
TNF-α; CRP 
Metabolic 
syndrome 
SP; calcitonin gene-related peptide; n-methyl-D-aspartate (NMDA) 
receptor/channel complex; sensory-motor C-fibres; nitric oxide (NO); 
reactive oxygen species (ROS); lipid peroxidation products; 
endogenous antioxidants; renin-angiotensin 
Cardiovascular 
pathology 
IL1; IL6; TNF-α; endothelin; SP; serum TBAR-materials; intracellular  
Glutathione (GSH); plasminogen activator inhibitor factor 1 (PAI-1); 
CRP; prostacyclin 2 (PGI2); Ca influx 
Magnesium 
supplementation 
Inflammation 
susceptibility 
Apoptosis; oxidative stress; TNF-α; IL6 
Anti-inflammation 
IL1β; IL1Ra; IL6; IL7; IL8; intercellular adhesion molecule 1 (ICAM-1); 
NF-κB; β-thromboglobulin (β-TG); platelet factor 4 (PF4); ATPase; 
HLA-DR, B7 Molecules; apolipoprotein E (ApoE); CCL2/4/5; 
chemokine (C-X-C motif) ligand 1 (CXCL1); neuronal injury; leukocyte 
migration; TNF-α 
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DL-PLA and HA-based materials have inadequate mechanical properties as load-bearing components19. 
Even some skeletal fixator materials with adequate strength can result in wide flaws because of their 
non-resorbability and different mechanics compared to cortical bones. For instance, some skeletal 
fixators have been reported to induce infection2, osteopenia19, a stress-shielding effect20 and an 
increased body sensitivity in responding to implant components such as nickel. The infection-created 
chronic inflammation can hinder the recovery from injury by decreasing the bone mass. Although often 
used as an “ideal” orthopaedic material, titanium, when worn as an “insert”, may lead to implant failure 
and hypersensitivity to metal debris21. Therefore, surgery is generally preferred after fracture healing to 
remove these implants. 
Table 2 Fixation products for orthopaedic application 
Product name Effect Reference 
Compression plate 
Increase the contact area 
Increase fragments stability 
Decrease stress on the implant 
[18,22] 
Screw 
Interfragmental compression 
Combine with plates to prevent displacement 
Support fragments 
[23,24] 
Pin and wire 
Fix small fragment or fracture 
Attach other devices 
[25–27] 
 
To address the side effects from implants, effective strategies have been introduced, such as 
accelerating the degradation of implant, early bone grafting and the early removal of implant28. Past 
decades have brought the emergence of biodegradable materials, such as biopolymers and 
biodegradable metallic substances, supplying implant materials made of zinc, iron and magnesium 
alloys, among others. Such materials can provide adequate mechanical stability to allow tissue 
regeneration while reducing inflammation, maintaining biocompatibility and avoiding secondary surgery 
by progressive resorption.  
The orthopaedic use of magnesium-based material was first reported at the start of the 20th century29. 
Many researchers were inspired to develop Mg as biodegradable implants for widened clinical 
application. In the late 1990s, reinvigorated interest in Mg-based alloys occurred in the realm of 
biomaterials since article numbers on this topic increased to 10-15 per week in international 
journals30. The beneficial performance of Mg compared to other metals is presented in Table 3.  
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Table 3 Properties of common absorbable metals. The present table is modified by reference [31] and 
permitted under CC BY 4.0 license. 
Metal 
Yield strength 
(MPa) 
Tensile strength 
(MPa) 
Maximum 
elongation (%) 
Corrosion rate 
(mm/year) 
Iron-based: Young’s modulus ~200 GPa, density ~7.8 g/cm3 
Pure iron as annealed 150 200 40 0.1 
Mg-based: Young’s modulus ~45 GPa, density ~1.7 g/cm3 
Pure Mg as extruded 30 100 7 8 
Mg-1Ca as extruded 135 240 10 12.5 
Mg-4Y-3RE(WE43) as 
extruded 
180 280 10 4.3 
Zinc-based: Young’s modulus ~100 GPa, density ~7.1 g/cm3 
Pure zinc as extruded 60 90 8 0.16 
Zn-1Mg as extruded 170 250 10 0.12 
Zn-3Cu-1Fe as extruded 210 270 20 0.13 
 
Magnesium alloys demonstrate a good combination of heightened mechanical strength and ductility 
together with a reduced stress-shielding effect32. Mg-based alloys are still under development, which is 
limited by their unsteady mechanical properties as well as degradation induced gas production and 
cavities. However, some reports indicate that the released gas and cavities have no long-term toxicity 
to the local tissue or effect on final clinical outcomes and still enable bone healing33,34. The application 
of Mg-based alloys has recently accelerated because of the benefits of improved corrosion resistance 
and mechanical properties resulting from rapidly advancing metallurgy technologies21. A series of 
preclinical studies and clinical applications of Mg-based materials regarding fracture fixation, bone flaps 
and cardiovascular stents has been performed across the world:  
1) Germany was the first country to report outcomes for a bioabsorbable magnesium-based screw 
(MgYReZr) used to treat hallux valgus. Because of no significant difference between Mg and Ti in 
a post-surgery trial, the MgYReZr screw was approved and commercialised with the Conformité 
11 Européene (CE) mark in 201333. Additionally, MgYReZr screws were applied in wide cases for 
the treatment of Madelung deformity in 201535, scaphoid fracture in 201636, distal fibular fracture 
in 201737 and medial malleolar fractures in 201838.  
2) The application of vascularised bone grafting with a specially designed high purity Mg screw was 
also reported to treat osteonecrosis of the femoral head (ONFH)39; This clinical trial was first 
conducted in China and indicated satisfactory results for the Harris hip score (HHS) and bone flap 
displacement imaged radiographically. Additionally, this trial greatly accelerated the product 
State of the art 
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registration process of pure Mg-based screws in the field of ONFH reconstruction surgery33. 
3) Mg-Ca-Zn screws were used for distal radius fractures; maxillofacial, sagittal and split ramus 
osteotomy; and set back surgery and reported to repair radius fractures. This clinical research on 
Mg-Ca-Zn screws accelerated their approval by the Korea Food and Drug Administration (KFDA) 
in April 2015 as the second officially approved Mg-based orthopaedic device40. This alloy was 
shown to bear more stress and to increase stability41. 
4) Magnesium and its alloys were studied as biodegradable cardiovascular stents. For instance, mg-
based scaffolds were developed as bioabsorbable scaffolds (BRS) to improve the permanent 
caging of the vessels, stent thrombosis (ST) and drug-eluting. Magmaris (Biotronik AG, Bülach, 
Switzerland) has received CE approval in Europe in June 2016, which is the first bio-corrodible 
metallic BRS available on the market42. In cardiovascular diseases, arteries can be clogged by 
plaque attached to their walls and made of calcium, cholesterol and fat. Angioplasty is performed 
to adjust the blood flow or stretch the vessel lumen by placing a mesh, tube-like scaffold to modify 
the vessel space. Materials for use in a cardiovascular stent require mechanical strength and no 
toxicity, at least when acting as a vessel scaffold in the long term, e.g., 6-12 months. To date, the 
gold standard for a cardiovascular stent is the 316L stainless steel model. Mg-based stents are 
credited for their potentially sustained mechanical support and no long-term toxicity or chronic 
inflammatory effect43,44. Another important advantage of Mg stents is that their flexibility is enough 
to allow surgical revascularisation after a vessel is stretched45. The Mg alloy Mg-2.2Nd-0.1Zn-0.4Zr 
was reported as promising for constructing stents when comparing to stainless steel or polymer 
because of its tissue compatibility and long-term (6 months) structural and mechanical integrity in 
vivo43. Arginine-leucine-based poly(ester urea-urethane)s (Arg-Leu-PEUUs) were used as bio-
functional coatings for the MgZnYNd stent and can significantly increase its corrosion resistance. 
The AE21 alloy consists of Mg, 2% aluminium and 1% rare earth metals (Ce, Pr, Nd) and meets 
most mechanical, biocompatibility and degradation/absorption performance requirements for use 
in a cardiac stent45. 
Because of their direct contact with the inner layer of vessels and the easy elution of substances 
from their surface by blood flow, stents are considered adaptable and efficient carriers for drugs or 
stimulation factors, in addition to their engineering utilisation. Key improvements will soon enhance 
the vascular compatibility of stents and adjust delivery efficiency via transforming the stent surface 
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or coating46. A coated Mg stent was used as a vehicle for drug delivery to the lesion area and as 
an angiogenesis stimulator in coronary angioplasty, for which the material characteristics can be 
improved through manufacturing techniques, e.g., equal-channel angular pressing (ECAP) and 
extrusion processing46,47. 
Because of its relatively high negative electrode potential, Mg tends to degrade through dissolving Mg 
ions gradually into the electrolytic aqueous physiological environment29,48. The in vivo degradation of 
Mg is complex and can be influenced by the type of protein49, material surface50 and cation composition51. 
The degradation products are circulated via blood flow, excreted through urine52, produce little change 
in blood composition and are harmless to the excretory functions of liver and kidneys53. However, Mg 
implants have been proven to degrade and accumulate Mg near the interface between tissues and 
implants54. However, such degraded Mg has positive effects, such as biocompatibility55 and an 
appropriate inflammation of the surrounding bone tissues56.  
2.3 Bone remodelling and the ECs-MSCs interaction 
Bone remodelling is defined as ossification or osteogenesis, continues throughout life and can be 
classified as intramembranous and endochondral ossification. The interplay between degraded Mg and 
bone remodelling is complicated because the bone fracture environment is controlled and nuanced by 
numerous cascades affecting the hierarchical structure, such as cellular activity, physical factors and 
proteins57,58. All of these surrounding cellular and microenvironmental factors contribute to the formation 
of the stem cell niche. The cell niche controls the quiescence, self-renewal and differentiation activity of 
stem cells; for instance, MSC niches enable homeostasis and maintain MSC populations59. Though the 
maintenance of mammalian stem cell niches is still not interpreted, the communication of cells is vital60. 
For instance, niches for MSCs are located close to ECs, vessel walls61 or perivascular areas, even 
though MSCs have different origins62.  
As indicated in Fig. 2, it is easy to conclude that both angiogenesis and mesenchymal stem cell (MSC) 
activity are involved in fracture healing.  
State of the art 
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Fig. 2 The process of fracture healing. 
The following events occur in fracture healing (Fig. 2):  
1) Inflammation activity: inflammation is induced by T and B cells and macrophages. 
2) MSCs within mesenchyme or the medullary cavity of a bone fracture initiate the intramembranous 
ossification via migration and differentiation. Once MSCs migrate into a specific area to act as 
osteoprogenitor cells and start to differentiate into osteoblasts63, MSCs show a variety of gene 
expression and cytokine secretions. For instance, collagen I is vital for the later mineralisation of 
hydroxyapatite64. Additionally, collagens affect the osteoid formation and cooperate with calcium 
salts and phosphorous to mineralise the bone tissue65. ECs can migrate into callus and develop 
micro-blood vessels.  
3) Bony callus: osteoblasts differentiated from MSCs convert cartilaginous into a bony callus.  
4) Bone remodelling: ultimately, bony callus hardens, fracture remodelling occurs, and the shape is 
restored to compact bone. 
Moreover, bone remodelling is influenced by a balance between the removal of old or damaged bone 
(resorption) and the subsequent formation of new bone (formation). Normally, the bone-resorptive 
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osteoclasts (OCs) and bone-forming osteoblasts (OBs) are in balance. But due to (e.g.,) age, gender, 
cancer or some other immune-system-activated diseases, this process can be disturbed and lead to 
local or systemic bone loss or increase66,67. Mg is believed to mediate OB and OC activities68. 
Considering the osteoblast precursor role of MSCs, Mg could also regulate MSCs before directly 
influencing OBs during bone remodelling. 
Hypoxia is an oxygen shortage and another important parameter in bone remodelling. Hypoxia is 
reported to regulate osteogenesis and angiogenesis (refer to section 2.3.1). This oxygen shortage is 
induced by blood clotting, but hypoxia could also be expected since Mg degradation is oxygen 
dependent69. In summary, ECs and MSCs can act as protagonists for angiogenesis and osteogenesis. 
Because of the broad and close relationship between MSCs, ECs, and hypoxia in the stromal cell niche, 
the effects of Mg on bone regeneration must be investigated in a more collective, complicated system. 
2.1.1. Mg and angiogenesis 
Angiogenesis defines the process by which new blood vessels form and in which the EC is the 
protagonist. For instance, ECs provide a functional basis by maintaining the integrity of the blood vessel 
inner surface70 and regulating homeostasis, vascular tone, coagulation, growth regulation and the 
modulation of blood flow56. Angiogenesis is an essential procedure for replacing damaged tissue such 
as fractured bone. Specifically, angiogenesis defines EC detachment, migration and reorganisation. The 
migration stage begins with adhesion and migration, while tube formation begins with adhesion, 
migration, protease activity and subsequent tubulogenesis (Fig. 3)72,73. In each step, ECs utilise 
corresponding growth factors to mediate proteinases leading to ECM degradation, integrins during 
adhesion and some morphogenetic molecules for cytoskeleton transformation. Mg is reported to 
influence angiogenesis. For instance, Mg can change the cell morphology via rearranging the actin 
cytoskeleton74.  
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Fig. 3 Angiogenesis process. 
2.1.2. Mg in the MSC-EC interaction and MSC fate  
Besides angiogenesis, the MSC is another protagonist in bone regeneration. MSCs are widely 
distributed in bone marrow, periosteum, adipose tissue, skin and dental tissues75. MSCs show 
multilineage potential, with the ability to self-replicate and differentiate into mesenchymal tissues, e.g., 
bone, cartilage, ligament, tendon, muscle and adipose tissue76. MSCs are stable with cell surface 
markers and markers of in vitro differentiation potential77. MSCs can mediate chronic inflammation and 
angiogenesis in the microenvironment of the host tissue by secreting cytokines, anti-inflammatory 
factors and immune receptors76.  
Though MSCs possess ideal natural capacities, their activity may differ when MSCs are under the 
influence of exogenous materials, e.g., biomaterials. Recent evidence indicates that the clinical outcome 
and future research could benefit from a concentration on improving and better understanding of cell 
migration, osteoblastic differentiation and the local environment. The homing and migration of MSCs are 
prerequisites to reach the target tissue and effectively express activity to regenerate and regulate a local 
fracture or normal tissue78. The resident MSCs in the knee joint synovium are proven to undergo 
proliferation and chondrogenic differentiation after MSC infusion in vivo79. Most cases, however, suggest 
that the homing of MSCs after cell seeding is insufficient75,80. Research suggests that this failure is 
related to a low expression of homing molecules, loss of migration molecules during expansion and an 
increase in heterogeneity80. After migration, a better understanding of the molecular mechanisms 
involved in the successive steps of MSC-osteoblastic differentiation appears to be crucial for enhancing 
bone regeneration81,82. In the microenvironment of the cell niche, besides the chemokine factors83, 
MSCs can also share Mg degradation products and hypoxia with ECs and eventually contribute to 
fracture healing81.  
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The present investigation of Mg effects on osteogenesis mostly focuses on MSCs or ECs alone. Mg was 
reported to suppress transcriptional remodelling84 while supporting the chondrogenic differentiation85 of 
bone marrow MSCs (BM-MSCs). The significance of the study may be limited mostly because the 
observations were not performed within the cell niche. 
2.1.3. The model for investigating the MSC-EC interaction 
The methodology to study the interaction in vitro depends on direct-contact coculture or indirect 
coculture to mimic the native cell niche86. To mimic optimally the native conditions, the donor influence 
between cell types must be minimised. For example, the osteoblast differentiation mechanisms show 
significant differences between humans and mice82. A direct-contact coculture system is necessary for 
investigating the effects of cell-cell contact, which is widely reported but still debated8788.  
ECs can be obtained from the human umbilical cord as human umbilical vein endothelial cells (HUVECs), 
which can produce relatively low contamination with smooth muscle cells and fibroblasts. HUVECs are 
widely used in the laboratory for studying angiogenesis function and endothelial pathology. The MSC 
donors can be different adult- or birth-associated tissues, such as adipose tissue (AT), bone marrow 
(BM), peripheral blood (PB), placenta, amnion, umbilical cord (UC) and umbilical cord blood (UCB)87. 
Human UC has prominent advantages, including ready availability that avoids ethical issues such as 
painful body invasion accompanied by pain and infection risk87. MSCs from UC are proven to possess 
faster self-renewal along with enhanced tissue repair and immunoregulation89,90. Moreover, UC-MSCs, 
compared to adult-derived sources, possess a variety of superior embryonic and biological capacities, 
such as improved proliferation, life span and differentiation potential87. MSCs can be isolated from the 
different UC compartments, such as Wharton's jelly (WJ)91, umbilical cord blood (UCB)92, vein, arteries, 
the UC lining and the subamnion and perivascular regions90. MSCs are easy and risk-free to isolate 
from UCB, but the MSC yield is very low93. Isolation from vein and arteries could bring the highest yield 
(~80%) but also contamination with ECs or blood cells while the perivascular area and WJ store 21% of 
the MSCs94. Therefore, MSCs are isolated by culturing the vein covered with perivascular tissues. The 
isolated MSCs are called human umbilical cord perivascular vein (HUCPV) cells.
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3 Motivation and objectives 
To gain a more comprehensive understanding of Mg effects, different HUCPV-HUVEC monocultures 
and cocultures were applied under normoxia and hypoxia conditions. The findings can also present the 
value of MSCs in regenerative medicine. To acquire purified MSC and EC populations, HUCPV cells 
and HUVECs were isolated from human umbilical cord and validated by surface markers. The 
differentiation potential of isolated ECs and MSCs were investigated by induced tube formation and 
osteogenesis, respectively. To mimic angiogenesis, the HUVEC type was investigated by the wound 
healing and tube formation assays. To investigate the respective effects of paracrine and cellular 
heterotypic contact between MSCs and ECs in the stem cell niche, transwell and direct-contact 
cocultures were used to grow HUCPV cells and HUVECs. In all models, the proliferation, metabolism, 
gene regulation and cytokine levels were investigated. 
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4 Materials and methods 
4.1 Magnesium degradation products 
4.1.1 Materials  
Table 4 Materials and equipment for Mg extraction and characterisation. 
Product Abbreviation Supplier 
99.95% Pure magnesium Pure-Mg Helmholtz-Zentrum Geesthacht, Germany 
Minimum essential medium, Eagle-
alpha modification 
α-MEM Fisher Scientific GmbH, Schwerte, Germany 
Foetal bovine serum for Human 
mesenchymal stem cells 
SC-FBS Biological Industries, Beit-Haemek, Israel 
100% n-Hexane 100% n-Hexane Merck, Darmstadt, Germany 
100% Acetone 100% Acetone Merck, Darmstadt, Germany 
100% Ethanol 100% Ethanol Merck, Darmstadt, Germany 
70% Ethanol 70% Ethanol Merck, Darmstadt, Germany 
Penicillin/Streptomycin P/S Fisher Scientific GmbH, Schwerte, Germany 
CO2 incubator Incubator 
Thermo Scientific – Fisher Scientific GmbH, 
Langenselbold, Germany 
Inductively coupled plasma mass 
spectrometry 
ICP-MS Agilent, Waldbron, Germany 
Cryoscopic osmometer Osmometer Gonotec, Berlin, Germany  
Sentron pH meter pH Meter Sentron Europe BV, VD Leek, Netherlands 
4.1.2 Samples cleaning and sterilisation and Mg extract preparation 
Pure-Mg (99.95%) was prepared by permanent mould gravity casting at Helmholtz-Zentrum Geesthacht 
(Geesthacht, Germany). T4 treated ingots were extruded into rods of 1 cm diameter. The rods were 
machined into a diameter of 0.9 cm. Disks were cut at a 1.5 mm thickness and then cleaned via 20 min 
sonication in 100% n-hexane, 100% acetone, 100% ethanol, sterilised in 70% ethanol, and further dried 
under clean-bench conditions. Mg-degradation products or extracts were produced according to EN ISO 
standards I. 10993-5:2009 and I. 10993-12:2012 (0.2 g of material/mL of extraction medium) for 72 h 
under physiological conditions (37 °C, 5% CO2, 20% O2, 95% relative humidity). The extraction media 
were α-MEM plus 15% SC-FBS and 1% P/S. Afterwards, the Mg, Ca and phosphorous (P) contents 
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were measured (Table 5) via ICP-MS. The Mg extract was diluted to 2, 4, and 8 mM with the same 
media as those used for extraction. The osmolality and pH of the diluted extract were tested by an 
osmometer and an ArgusX pH meter, respectively.  
 
Table 5 Characterisation of Mg degradation products. *Values were obtained from calculations or the 
cell culture media composition provided by the manufacturer. 
 
Extract Magnesium 
(mM) 
Calcium 
(mM) 
Natrium 
(mM) 
Phosphorus 
(mM) 
Osmolality 
(osmol/kg) 
pH 
Control 0.81* 1.80* 143.43* 1.01* 0.290±0.003 7.55±0.005 
1× 70.37±1.16 0.63±0.11 150.72±5.23 0.26±0.09 0.41±0.001 8.06±0.01 
2 mM Mg 2.00* 0.65±0.11 150.60±5.14 0.27±0.09 0.30±0.003 7.59±0.06 
4 mM Mg 4.00* 0.68±0.10 150.39±5.00 0.29±0.09 0.31±0.002 7.59±0.07 
8 mM Mg 8.00* 0.75±0.10 149.97±4.70 0.34±0.08 0.31±0.003 7.67±0.03 
4.2 The isolation of human umbilical cord  
4.2.1 Materials and ethical approval 
Ethical approval for the isolation of the cells was obtained from the Ethik-Kommission der Ärztekammer 
Hamburg (PV4058). 
Table 6 Materials and equipment used for cell isolation. 
Name Abbreviation Supplier 
Endothelial cell growth medium ECGM PromoCell, Heidelberg, Germany 
Endothelial cell growth supplement  ECGS kit PromoCell, Heidelberg, Germany 
Minimum essential medium, Eagle-alpha 
modification  
α-MEM Fisher Scientific GmbH, Schwerte, Germany 
Foetal bovine serum optimised for human 
mesenchymal stem cells 
SC-FBS Biological Industries, Beit-Haemek, Israel 
Penicillin/Streptomycin P/S Fisher Scientific GmbH, Schwerte, Germany 
Phosphate-buffered saline PBS 
Thermo Scientific – Fisher Scientific GmbH, 
Langenselbold, Germany 
Foetal bovine serum FBS Biochrom, Berlin, Germany 
NuncTM EasYFlaskTM 175 cm2 T175 flask Fisher Scientific, Roskilde, Denmark 
Collagenase (from Clostridium histolyticum 
Type IA 
Collagenase Sigma-Aldrich, Munich, Germany 
Nalgene sterile syringe filter, 0.2 μm  Syringe filter Fisher Scientific GmbH, Schwerte, Germany 
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4.2.2 The structure of the human umbilical cord  
The human umbilical cord contains two artery vessels and one vein vessel, which are covered with 
perivascular Wharton’s jelly (WJ). WJ is the gelatinous substance that insulates umbilical blood vessels, 
intermediate WJ, cord lining WJ and maternal sheath with outer covering from the inside (Fig. 4b)95, 96. 
The perivascular region is the closest surrounding the vessels and is part of the WJ matrix, which has 
been the focus area for UC-MSC isolation (Fig. 4c). 
Fig. 4 Dissection of human umbilical cord (UC) shown (a) photographically, (b) as a schematic diagram, 
(c) UC cross-section, (d) endothelial cells and endothelium in a blood vessel. Fig. 4b is adapted from 
[97] and premised by Wiley Publication. Copyright© 2000-2019 by John Wiley & Sons, Inc. 
4.2.3 HUCPV cell isolation 
Referencing the WJ distribution shown in Fig. 4b and the cell distribution indicated in Fig. 4c, HUCPV 
cells were expanded by cultivating the arteries with perivascular WJ: 
1) The blood was removed via washing with sterilised PBS. 
2) The umbilical cord was dissected to acquire the arteries and vein. 
3) Both ends of the arteries were ligated with sterilised surgical thread. 
4) The ligated arteries were cultured in a T175 flask with α-MEM-complete medium (supplemented 
with 15% SC-FBS and 1% P/S). 
5) The cell proliferation was observed to avoid more than 70% confluence (possible cell 
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differentiation). 
4.2.4 HUVEC isolation 
HUVECs can be derived from the endothelium of veins from the umbilical cord via digesting the tissue 
connection between the endothelium, internal elastic lamina and smooth muscle cells (Fig. 4d). 
Collagenases are usually used as a ferment dispase (proteolytic enzymes) for digesting cells. Compared 
to other collagenases, type I possesses the lesser protease activity and was applied as a 
ferment dispase to derive ECs from the vein lumen98. 
HUVECs were acquired and cultured based on the following procedures: 
1) Blood was washed by sterilised PBS. 
2) The umbilical cord was dissected to acquire the vein. 
3) The inner lumen of the vein was flushed by injecting sterilised PBS. 
4) Collagenase solution (0.2% w/v) was injected, and the solution filled the lumen of the vein.  
5) The ends of the vein were ligated, and the vein was incubated in 37 °C-sterilised PBS for 15 min. 
6) The vein lumen was flushed with ECGM-complete medium (ECGM supplemented with ECGS and 
10% FBS). 
7) The flushed medium was centrifuged (1,000 rpm, 10 min). 
8) The centrifuged cell pellet was resuspended and cultured in ECGM-complete medium with 5,000 
cells/cm2 under physiological conditions (37 °C; 95% air and 5% CO2, saturated with H2O). 
9) The cultures were examined for typical “cobblestone” morphology every 24 h, and possible 
contamination (such as a blood clot) was removed via washing with PBS.  
4.3 HUCPV and HUVEC characterisation  
4.3.1 Immunophenotyping 
HUCPV cells and HUVECs can be efficiently immunophenotyped by confirming the expression of 
specific markers via flow cytometry. Considering the location and the surroundings of HUCPV cells and 
HUVECs in the umbilical cord, the potential contamination from local cell types (e.g., blood cells) was 
also considered. Thus, in the immunophenotyping, the cluster of differentiation (CD) 31, CD 90 and CD 
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105 were applied as positive controls (full molecule names can be found in Table 8). Moreover, CD 45 
and CD 31 were used as negative controls for hematopoietic and endothelial (only in the HUCPV cell 
isolate) contamination, respectively. The natural Y shape of an antibody can be divided into three 
sections, with the Fc section a binding region for endogenous Fc receptors on the cellular surface and 
the binding site for the secondary antibody99. In addition to Fc, nonspecific adhesive material, as an 
example, might undesirably bind to the cell membrane. Therefore, to distinguish between positive and 
negative populations and between nonspecific and specific antibody signals100, an isotype control 
containing corresponding mouse immunoglobulin G conjugated with the same fluorochrome was used. 
Thus, the isotype controls should match the primary antibody regarding the host species, the class of 
heavy and light chains and the fluorochrome conjugate and molecule number per immunoglobulin (IgG), 
as well as derive from the same manufacturing lot100,101. Consequently, mouse immunoglobulin G (IgG) 
was used as an isotype control (Table 8). 
Materials 
Cells resuspended in PBS served as a blank control. BSA in PBS (1% w/v) was prepared for use as a 
staining buffer. All antibodies and isotypes were purchased from Thermo Fisher (Fisher Scientific GmbH, 
Germany), as listed in Table 7 and 8. All markers are distributing on the cell surface. 
 
Table 7 Materials for flow cytometry 
Product Abbreviation Supplier 
Bovine serum albumin  BSA Carl Roth, Karlsruhe, Germany 
Phosphate-buffered saline PBS 
Thermo Scientific – Fisher Scientific GmbH, 
Langenselbold, Germany 
0.05% Trypsin-EDTA  Trypsin Life Technologies, Schwerte, Germany 
Bio-Rad S3e™ Cell Sorter Flow cytometer Bio-Rad Laboratories, Munich, Germany 
Round-bottom polystyrene tubes Flow cytometer 
tubes 
Bio-Rad Laboratories, Munich, Germany 
Propidium iodide PI Bio-Rad Laboratories, Munich, Germany 
Prosort™ software for S3e™ Cell 
Sorter, version 1.5 
ProSort software Bio-Rad Laboratories, Munich, Germany 
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Table 8 Antibody information 
Population Purpose Marker Antigen Catalogue Conjugate Isotype Reference 
HUCPV 
Control for 
endothelial 
contamination 
CD 31 
Platelet 
endothelial 
cell 
adhesion 
molecule-1 
MA119769 PE 
Mouse 
IgG1/#559320 
[87] 
Control for 
hematopoietic 
cells 
CD 45 
Leukocyte 
common 
antigen 
MA119569 FITC 
Mouse 
IgG1/#555748 
[102, 103] 
Negative 
control 
CD34 
Sialomucin-
like 
adhesion 
molecule 
MA119645 PE 
Mouse 
IgG1/#559320 
[104, 105] 
CD 54 
Intercellular 
adhesion 
molecule 1 
MA110250 PerCP 
Mouse 
IgG2b/#558304 
[87] 
Positive 
CD 90 
Thy-1 cell 
surface 
antigen 
A15761 FITC 
Mouse 
IgG1/#555748 
[106] 
CD 
105 
Endoglin MA119594 FITC 
Mouse 
IgG2a/#555573 
[87] 
HUVEC 
 
 
Control for 
hematopoietic 
cells 
CD 45 
Leukocyte 
common 
antigen 
MA119569 FITC 
Mouse 
IgG1/#555748 
[107] 
Positive 
CD 31 
Platelet 
endothelial 
cell 
adhesion 
molecule-1 
MA119769 PE 
Mouse 
IgG1/#559320 
[108] 
CD 
105 
Endoglin MA119594 FITC 
Mouse 
IgG2/#555573 
[108] 
Immunophenotyping is a process using antibodies to identify cells based on the types of antigens or 
markers on the surface of the cells. The cell population was identified by the expression of specific 
markers as positive, negative and isotype controls using flow cytometry. The schematic about 
immunophenotyping is introduced in Appendix (Fig. S1).  
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Procedures 
1) Cells were dissociated by 0.05% trypsin-EDTA.  
2) The dissociated cells were adjusted to 500,000 cells per 20 μL of staining buffer and stained with 
the following antibody solutions according to the flow cytometry panel designed for HUCPV cells 
and HUVECs (Table 8). The FL channels are dependent on the fluorescence spectrum of 
conjugated dyes and detection sensors. 
a) CD 105: 5 μL for 5*105 cells, FITC (FL1 channel)  
b) CD 54: 2 μL for 5*105 cells, PerCP (FL4 channel) 
c) CD 31: 2 μL for 5*105 cells, PE (FL2 channel) 
d) CD 34: 2 μL for 5*105 cells, PE 
e) CD 45: 2 μL for 5*105 cells, FITC  
f) CD 90: 2 μL for 5*105 cells, FITC  
3) Samples were incubated at 4 ºC for 30 min in darkness on ice. 
4) Cells were washed once with warm staining buffer and centrifuged at 13,000 rpm for 5 min. 
5) Samples were resuspended in a 5 mL of ice-cold PBS in round bottom flow cytometer tubes.  
6) The forward scatter (FSC) and side scatter (SSC) were determined by blank controls. The diameter 
of the cell can be measured via FSC, which is proportional to the light diffraction around the cell. 
SSC can provide information about the internal complexity (i.e. granularity) of the cells109. At some 
extent, FSC and SSC can represent the heterogeneity within the cell population. 
7) The corresponding fluorescence intensity of different groups (positive, blank, negative and isotype) 
and their propidium iodide (PI) staining were detected via the collection of 5,000 to 10,000 events 
per assay. 
8) Unspecific binding was excluded based on no significant difference between the isotype and blank 
controls. The results were obtained by compensating the marker expression with the blank controls, 
PI staining or single staining if cells were double stained with two fluorochromes. By gating >95% 
of the events in blank controls, the results were finally acquired after applying the gate to the other 
assays using ProSortTM software. 
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4.3.2 Differentiation potential 
Osteogenesis inducement 
To characterise further the mesenchymal stem cells, HUCPV osteogenic potential was induced in 
medium containing osteogenic components such as 1α, 25-dihydroxyvitamin D3 (Vit D3), β-
glycerophosphate, L-ascorbic acid and dexamethasone. Method 1, 2 and 3 contain different osteogenic 
components were applied to validate the osteogenesis potential of isolated HUCPV cells91, 110. HUCPV 
cells (passage 5th to 8th) were seeded as 5,000 cells/cm2 in 24-well plates for 21 days. Every 7 days, the 
supernatant and cells were used for investigating DNA, alkaline phosphatase (ALP) activity and ARS 
staining.  
Angiogenesis inducement 
The ability to develop capillary structure is a vital step during angiogenesis111. To form three-dimensional 
vascular networks (capillary-like networks), specific molecules in the “matrix-integrin-cytoskeletal 
signalling axis” are involved in such angiogenesis assembly112. The tube formation assay is a typical 
platform to investigate this reorganisation stage. This assay needs to be optimised because of the 
variation induced by cell types, experimental media and treatment compounds. HUVECs were first 
expanded to 70-80% confluence (exponential phase) to obtain more activated cells113 and then starved 
in ECGM-complete medium supplemented with low FBS (1%) for 24 h to synchronise the life cycle in 
the G0/G1 phase. One requirement for EC capillary development is the extracellular matrix (ECM). The 
usual ECM coating requires a large amount of matrix to create a thick layer on a flat surface because 
the matrix is viscous. An adapted thin-layer assay (TLA)114 was applied, as indicated in tube formation 
assay (refer to Fig. 8 in section 4.13). 
4.4 Cell expansion 
HUVECs were cultured in ECGM-complete medium as 5,000 cells/cm2 in physiological conditions until 
90% confluence or up to passage 6. The HUCPV cells were cultured in α-MEM-complete medium (α-
MEM plus 15% SC-FBS and 1% P/S) as 2,000 cells/cm2 in physiological conditions before 80% 
confluence or up to passage 12. 
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4.5 Coculture system 
To understand the cytokine effects and contact dependency during coculture, HUCPV cells and 
HUVECs were cocultured as non-contact (transwell) and contact (cell mixed) coculture models, 
respectively (Fig. 5). The well areas of the low chamber and insert were 2 and 0.33 cm2, respectively. 
The well areas of the 24- and 96-well plates were 2 and 0.32 cm2, respectively. Based on the results of 
the medium test (Section 5.2), the α-MEM-complete medium was applied as the coculture medium.  
In the non-contact or transwell coculture and the wound healing assay, HUCPV cells and HUVECs 
(80,000:20,000 cells per well) were seeded in the inserts and the bottom chamber of 24-well plates 
respectively. Culture medium at a volume of 1.5 mL and containing or not containing Mg degradation 
product was refreshed every 3 days.  
In direct-contact (i.e., contacting) coculture, HUCPV cells and HUVECs (5,000:1,000 cells per well) were 
seeded together in 96-well plates for ELISA and DNA assays. HUCPV cells and HUVECs 
(80,000:20,000 cells per well) were seeded in 24-well plates for flow cytometry, Alizarin Red S staining 
(ARS) and the determination of alkaline phosphatase (ALP) activity. Two hundred microlitres of culture 
medium or Mg degradation product was used in 96-well plates or 1.5 mL in 24-well plates and refreshed 
every 3 days. The continuous presence of HUCPV cells and HUVECs in the direct-contact coculture 
throughout the culture period was monitored by the phenotypic expression of specific surface markers 
(CD 90 (Thy1 cell surface antigen) and CD 31 (platelet endothelial cell adhesion molecule-1) for HUVEC 
and HUCPV cells, respectively) via flow cytometry.  
Both coculture models were used under physiological conditions. Hypoxia and normoxia were obtained 
under 5% and 20% O2, respectively. All further assays or sample collections were performed on days 1, 
4 and 7. Eventually, the continuous presence of HUCPV cells and HUVECs in the direct-contact 
coculture was monitored up to 7 days by the phenotypic expression of specific markers (CD 90 and CD 
31 for HUVECs and HUCPV cells, respectively) via flow cytometry. 
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Fig. 5 The coculture systems: (a) transwell coculture and (b) direct-contact coculture. 
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4.6 Deoxyribonucleic acid (DNA) quantification 
4.6.1 Materials 
Table 9 Materials for DNA quantification 
Name Abbreviation Supplier 
2′-(4-Ethoxyphenyl)-6-(4-methyl-1-piperazinyl)-
1H,3′H-2,5′-bibenzimidazole 
Bisbenzimide Sigma-Aldrich, Munich, Germany 
Sodium hydroxide pellets NaOH Sigma-Aldrich, Munich, Germany 
Ethylenediaminetetraacetic acid EDTA Sigma-Aldrich, Munich, Germany 
Tris(hydroxymethyl)aminomethane Tris Sigma-Aldrich, Munich, Germany 
Human genomic DNA gDNA Sigma-Aldrich, Munich, Germany 
Sodium chloride NaCl Merck, Darmstadt, Germany 
Hydrochloric acid  HCl Merck, Darmstadt, Germany 
NanoDropTM 2000c spectrophotometer Nanodrop 
Thermo Scientific – Fisher Scientific 
GmbH, Langenselbold, Germany 
Thermomixer® comfort Thermomixer Eppendorf, Hamburg, Germany 
VICTOR3 multilabel plate reader Plate reader PerkinElmer, Waltham, USA 
Cellstar® 24-well cell culture plate 24-Well plate 
Greiner Bio-One, Kremsmünster, 
Austria 
Minimum essential medium, Eagle-alpha 
modification 
α-MEM 
Fisher Scientific GmbH, Schwerte, 
Germany 
Kimberly-Clark™ professional tissue wipers 
Low-lint 
paper 
Thermo Scientific – Fisher Scientific 
GmbH, Langenselbold, Germany 
4.6.2 Procedures 
Cell proliferation can assess physiological cell health and responses to foreign substances. DNA levels, 
synthesis, or cellular metabolism as well as proliferation-specific proteins can be typical markers. DNA 
investigation is accurate and simple because the amount of DNA in each cell remains constant for a 
given cell line or cell type. The DNA content can be quantified by spectrophotometry (e.g., Nanodrop 
technique) or fluorometry (e.g., bisbenzimide fluorochrome). The bisbenzimide was chosen for DNA 
quantification because of the more stable DNA results observed with bisbenzimide. 
The bisbenzimide method was performed with the following steps:  
1) Variously treated cells were extracted in lysis buffer (25 mM NaOH, 0.2 mM EDTA) and incubated 
for 5 min at 37 °C.  
2) Lysate was heated and centrifuged on the thermomixer at 98 °C and 1,000 rpm for 1 h and cooled 
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to 15 °C at 700 rpm.  
3) Lysate was buffered with an equal volume of neutralisation solution (40 mM Tris/HCl, pH 5.5) and 
centrifuged at 13,000 rpm for 1 min.  
4) Depending on the predicted DNA concentration and the linear range of standard curves, lysate 
was diluted with varying quantities of dilution buffer (2.5 M NaCl, 19 mM sodium citrate, pH 7). 
DNA standard curves were calculated by the fluorescence intensities and the concentrations of 1:2 
serial dilutions of the genomic DNA (gDNA). 
5) Lysis buffer and neutralisation solution were used as the blank control. Diluted samples (including 
standards and blank controls), DNA working buffer (2 M NaCl, 15 mM sodium citrate, pH 7) and 
bisbenzimide solution (2 µg/mL bisbenzimide in DNA working buffer) were prepared in a 2:1:1 ratio 
in 200 µL and ultimately pipetted into 96-well plates. 
6) Then, the mixed solutions were incubated in the dark for 15 min. The DNA content was quantified 
by reading the bisbenzimide fluorescence with a plate reader at excitation (Ex) 355 nm and 
emission (Em) 460 nm. The DNA concentration was calculated with a fluorescence standard curve 
for DNA content. The same amount of vehicle buffers was applied as that used in the blank controls. 
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4.7 Metabolism assay 
4.7.1 Materials 
Table 10 Materials for mitochondrial susceptibility and membrane potential assays 
Name Content Supplier 
Digitonin detergent solution for 
permeabilising cells 
Digitonin 
Thermo Scientific – Fisher Scientific GmbH, 
Langenselbold, Germany 
Antimycin A from Streptomyces 
species 
Antimycin A Sigma-Aldrich, Munich, Germany 
Rhodamine 123  R123 Sigma-Aldrich, Munich, Germany 
VICTOR3 multilabel plate reader Plate reader PerkinElmer, Waltham, USA 
Sunrise™ Tecan microplate reader 
Microplate 
reader 
Tecan, Männedorf, Switzerland 
PreMix WST-1 Cell Proliferation Assay 
System 
WST-1 kit Takara Bio Inc., Kusatsu, Japan 
 
4.7.2 Metabolism 
Mitochondria play a vital role in eukaryotic cellular metabolism since the majority of ATP is generated 
through oxidative phosphorylation in mitochondria115. During energisation, electrons are transported, 
crossing from electron donors (complex I to IV in Fig. 6) to electron acceptors such as oxygen. The 
mitochondrial electron transport chain creates an electrochemical gradient and generates the 
mitochondrial membrane potential (ΔΨm).  
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Fig. 6 WST-1 and rhodamine 123 involvement in metabolism. 
 
Rhodamine 123 and WST-1 were used to investigate cellular metabolism. Because the mitochondrial 
inner membrane is negatively charged via the electron transport chain, and rhodamine 123 (R123) is 
cationic and lipophilic, R123 can diffuse through and selectively accumulate across the mitochondrial 
membrane in proportion to the membrane potential116. As an inhibitor of mitochondrial electron transport 
between cytochromes B and C (complex III)117, antimycin A eliminates the selective mitochondrial 
association with rhodamine 123, which triggers loss of ΔΨm118, 119. The application of rhodamine 123 in 
fluorescence microscopy to monitor ΔΨm has been reported in individual living cells116. Digitonin 
effectively water-solubilises lipid and can solubilise membrane proteins in the lipidic double layer, 
precipitate cholesterol and permeabilise cell membranes120, 121. Digitonin did not affect the mitochondrial 
membrane in cytofluorometric analysis122. WST-1, as a classical tetrazolium salt, can be cleaved by 
complex I in the mitochondrial, changing from a slight pink material into yellow formazan (Fig. 6). 
Additionally, recent studies indicate that WST-1 can undergo transformation by the ubiquinone cycle in 
the cytoplasm represented by the cytoplasm membrane potential.  
The effects of glucose and galactose on mitochondria-related experiments must be considered because 
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two ways are involved in generating ATP in mammalian cells, namely mitochondrial (oxidative 
phosphorylation) and non-mitochondrial (glycolysis). To increase the detection of xenobiotic-induced 
mitochondrial effects, cells have been forced to rely on mitochondrial oxidative phosphorylation rather 
than glycolysis123. Thus, a further mitochondrial-related assay was performed under galactose-excluded 
conditions.  
4.7.3 Rhodamine 123 assay 
The mitochondrial membrane potential (Δψm) in HUVEC monoculture model was measured by the 
retention of R123 fluorescence. HUVEC monocultures were seeded as 5,000 cells per well in 96-well 
plates. The cocultures were built as described in the “Coculture system” section. All the samples were 
cultured with Mg degradation products or α-MEM-complete medium (as control) at 37°C in 20 or 5% O2. 
After the treatment period (e.g., on Day 1, 4 and 7), 30 nM of digitonin was added to each well, and the 
plates were incubated for 5 min on ice122. Rhodamine 123 (10 µg/mL in PBS) was added to each well, 
and the plates were incubated for 10 min at room temperature (RT). Rhodamine 123 was excited (λEx) 
at 510 nm, and the fluorescence emission was detected (λEm) at 534 nm with a plate reader as Rh T0. 
Antimycin A was added at a concentration of 10 μM to the cells for 1 min on ice, and the fluorescence 
was detected after every 2 min for 3 times as Rh T2, T4 and T6. The value of Δψm was calculated by 
the difference between T0 and the average of T2 to T6. The variation induced by cell numbers between 
each treatment was normalised by the DNA content. 
4.7.4 WST-1 assay 
The metabolism represented by WST-1 was determined from the amount of formazan produced (Fig. 
6). HUVEC monocultures were seeded as 5,000 cells per well in 96-well plates. Cocultures were seeded 
as described in the “Coculture system” section. All samples were cultured with Mg degradation products 
or α-MEM-complete medium (as control) at 37 °C in 20 or 5% O2. After the treatment period (e.g., on 
Days 1, 4 and 7), WST-1 solution (1:10 in fresh control medium) was added as 500 µL per well to 24-
well plates, and the plates were incubated for 30 min in 20% and 5% O2. The absorbance of 100 µL of 
each sample was measured using a microplate reader at 450 nm. The variation induced by cell number 
differences between treatments was normalised by the DNA content. Absorbance was normalised by 
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the DNA content from a DNA quantification assay performed to reduce the variation in cell numbers. 
4.8 Real-time quantitative polymerase chain reaction (RT-qPCR) 
To investigate gene regulation, a particular RNA was quantified by two-step RT-qPCR. First, RNA was 
transcribed into complementary DNA (cDNA) from a total RNA sample. cDNA was then detected via 
measuring the amplification of DNA with SYBR Green fluorescent dye. Translation and RT-qPCR are 
introduced in Appendix (Fig. S2).  
4.8.1 Materials 
Table 11 Materials for RT-qPCR 
Material Abbreviation Supplier  
RNeasy mini kit RNeasy kit Qiagen, Hilden, Germany 
Omniscript RT kit RT kit Qiagen, Hilden, Germany 
cDNA primer (Table 13) Primer Eurofins MWG Operon, Ebersberg, Germany 
SsoFastTM Evagreen® supermix 
Ssofast 
supermix 
Bio-Rad Laboratories, Munich, Germany 
CFX96 TouchTM real-time PCR 
detection system 
PCR detector Bio-Rad Laboratories, Munich, Germany 
CFX ManagerTM software version 3.1 CFX software Bio-Rad Laboratories, Munich, Germany 
NanoDropTM spectrophotometer Nanodrop  
Thermo Scientific – Fisher Scientific GmbH, 
Langenselbold, Germany 
 
4.8.2 Ribonucleic acid (RNA) extraction and quality control of RNA 
First, total RNA was extracted by binding RNA to silicon-based columns and washing off other fat and 
proteins using the QIAshredder and RNeasy kit. The RNA concentration was measured using a 
Nanodrop spectrophotometer. The RNA concentration was measured by the absorbance at 260 nm 
(A260). The ratio of the absorbance at 260 to that at 280 nm (A260/280) was used to ensure its purity. 
4.8.3 Complementary DNA (cDNA) synthesis  
cDNA was produced via reverse transcription (RT). The cocktail for each sample of the same treatment 
was prepared with the same amount of RNA (50-100 ng) to produce comparable results. The cocktail 
was prepared with the RT kit and incubated at 37 °C for 60 min by the PCR detector (Table 12). The 
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cDNA product was diluted 1:40 with nuclease-free water and stored at -20 °C until use. 
 
Table 12 Cocktail for cDNA synthesis in RT 
Name Amount 
10x Buffer RT  2 μL  
dNTP mix  2 μL  
RNase inhibitor  1 μL  
Omniscript reverse transcriptase  1 μL  
RNA template  50 or 100 ng  
RNase-free water  Compensated for RNA volume  
Cocktail final volume 20 μL 
4.8.4 Primers and RT-qPCR 
Primers were designed via Primer 3 (version 4.0.0) or found in the RTPrimerDB database and 
purchased from Eurofins NDSC Food Testing Germany GmbH (Hamburg, Germany). The following 
targets were used, and their sequences are presented in Table 13. Beta-2-microglobulin (B2M) and actin 
beta (ACTB) were used as reference genes. 
 
Table 13 Primers for RT-qPCR. Annealing temperature was 60°C for all designed primers. 
Full name Abbreviation Sequence 
Angiogenin ANG 
Forward: 5’-CATCATGAGGAGACGGGG-3’ 
Reverse: 5’-TCCAAGTGGACAGGTAAGCC-3’ 
vascular cell adhesion molecule 1 VCAM1 
Forward: 5’-CGTCTTGGTCAGCCCTTCCT-3’ 
Reverse: 5’-ACATTCATATACTCCCGCATCCTTC-3’ 
Vascular endothelial growth factor B 
isoform 
VEGFB186 
Forward: 5’-GCTCTTCTGCCATCCCTTGT-3’ 
Reverse: 5’-TAGTGAGGGGAGGAAGAGCC-3’ 
Vascular endothelial growth factor 
receptor 1 
FLT1/VEGFR1 
Forward: 5’-GGGCTGAAACCATGTGCAAG-3’ 
Reverse: 5’-GCCAAAGATGCACTCCTCCT-3’ 
Vascular endothelial growth factor 
receptor 2 
KDR/VEGFR2 
Forward: 5’-GGCATGGGGTCTGTTCTGAA-3’ 
Forward: 5’-TTGGCCAGGAGACACGTAAC-3’ 
Transmembrane 4 CD9 
Forward: 5’-CCTGCTGTTCGGATTTAACTTCA-3’ 
Forward: 5’-TGGTCTGAGAGTCGAATCGGA-3’ 
Ezrin EZR 
Forward: 5’-ATGCCCCACGTCTGAGAATC-3’ 
Forward: 5’-TCCTGCGGCGCATATACAAC-3’ 
Integrin subunit alpha 1 ITGA1 
Forward: 5’-GTGCTTATTGGTTCTCCGTTAGT-3’ 
Reverse: 5’-GCCCACAAGCCAGAAATCCT-3’ 
Integrin subunit alpha 2 ITGA2 
Forward: 5’-TGTTGTTTGGCCTACAATGTTGG-3’ 
Reverse: 5’-CAACCAGTAACCAGTTGCCTT-3’ 
Integrin subunit alpha 3 ITGA3 
Forward: 5’-GGGATCCTGCCTAAGGTTGTCT-3’ 
Reverse: 5’-CCTTCTTTCTAGTTCCTTTGCTGTTG-3’ 
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Table 13 (Continued)   
Full name Abbreviation Sequence 
Integrin subunit alpha M ITGAM 
Forward: 5’-GTGAAGCCAATAACGCAGC-3’ 
Reverse: 5’-TCTCCATCCGTGATGACAAC-3’ 
Interleukin 8 IL8 
Forward: 5’-ATAAAGACATACTCCAAACCTTTCCAC-3’ 
Reverse: 5’-AAGCTTTACAATAATTTCTGTGTTGGC-3’ 
Matrix metallopeptidase 13 MMP13 
Forward: 5’-TTTCAACGGACCCATACAGTTTG-3’ 
Reverse: 5’-CATGACGCGAACAATACGGTTA-3’ 
TIMP metallopeptidase inhibitor 1 TIMP1 
Forward: 5’-GGAGAGTGTCTGCGGATACTTC-3’ 
Reverse: 5’-GCAGGTAGTGATGTGCAAGAGTC-3’ 
Hypoxia-inducible factor 1 alpha 
subunit 
HIF1A 
Forward: 5’-GGCGCGAACGACAAGAAAAAG-3’ 
Reverse: 5’-CCTTATCAAGATGCGAACTCACA-3’ 
Hypoxia-inducible factor 2 alpha 
subunit 
HIF2A 
Forward: 5’-TACAAGGAGCCCCTGCTGTC-3’ 
Reverse: 5’-TGCTGGATTGGTTCACACATG-3’ 
Basic fibroblast growth factor FGFb/FGF2 
Forward: 5’-AAAAGGCAAGATGCAGGAGA-3’ 
Reverse: 5’-TTTTGCAGCCTTACCCAATC-3’ 
Interferon gamma IFNγ 
Forward: 5’-TCGGTAACTGACTTGAATGTCCA-3’ 
Reverse: 5’-TCCTTTTTCGCTTCCCTGTTTT-3’ 
Ca-activated neutral protease 1 CAPN1 
Forward: 5’-GGTGCGGCTAGAGACCATGT-3’ 
Reverse: 5’-CTTGGCAGACGAGGAGGGAG-3’ 
Claudin 16 CLD16 
Forward: 5’-TGGTAACTCGAGCGTTGATG-3’ 
Reverse: 5’-TTCACGCAGTCAAGACCAAG-3’ 
Nitric oxide synthase NOS2 
Forward: 5’-ATGCTCAGCTCATCCGCTAT-3’ 
Reverse: 5’-CGATGCACAGCTGAGTGAAT-3’ 
Cythohesin2 CYTH2 
Forward: 5’-GAGGACGGCGTCTATGAACC-3’ 
Reverse: 5’-ACCTCGCTCATGGCTTCAC-3’ 
Selectin SELE 
Forward: 5‘-TGTGGGTCTGGGTAGGAACC-3‘ 
Reverse: 5‘-AGCTGTGTAGCATAGGGCAAG-3‘ 
Bone morphogenetic protein 4 BMP4 
Forward: 5’-ATGATTCCTGGTAACCGAATGC-3’ 
Reverse: 5’-CCCCGTCTCAGGTATCAAACT-3’ 
Bone morphogenetic protein 6 BMP6 
Forward: 5’-AGCGACACCACAAAGAGTTCA-3’ 
Reverse: 5’-GCTGATGCTCCTGTAAGACTTGA-3’ 
Platelet-derived growth factor aa PDGFA/PDGFaa 
Forward: 5’-CCAGCGACTCCTGGAGATAGA-3’ 
Reverse: 5’-CTTCTCGGGCACATGCTTAGT-3’ 
Osteoprotegerin OPG 
Forward: 5’-CGCTCGTGTTTCTGGACAT-3’ 
Reverse: 5’-GGACATTTGTCACACAACAGC-3’ 
Collagen type XII alpha 1 chain Col12A1 
Forward: 5’-CAGGTTCCGGCTAACACATT-3’ 
Reverse: 5’-GCGCAAACATCTCAGAAACA-3’ 
Endothelial differentiation related 
factor 1 
EDF1 
Forward: 5’-GCAAGGGGCTTACGCAGAA-3’ 
Reverse: 5’-CGCTCTCATAGTCCGCGAT-3’ 
Integrin subunit alpha 1 ITGA1 
Forward: 5’-GTGCTTATTGGTTCTCCGTTAGT-3’ 
Reverse: 5’-GCCCACAAGCCAGAAATCCT-3’ 
Collagen type I alpha 1 chain COL1A1 
Forward: 5’-AAGACATCCCACCAATCACC-3’ 
Reverse: 5’-GCAGTTCTTGGTCTCGTCAC-3’ 
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Table 13 (Continued) 
Full name Abbreviation Sequence 
TIMP metallopeptidase inhibitor 2 TIMP2 
Forward: 5’-ACCCTCTGTGACTTCATCGTGC-3’  
Reverse: 5’-GGAGATGTAGCACGGGATCATG-3’ 
C-C motif chemokine ligand 2 CCL2 
Forward: 5’-AGAATCACCAGCAGCAAGTGTCC-3’ 
Reverse: 5’-TCCTGAACCCACTTCTGCTTGG-3’ 
Beta-2-microglobulin B2M 
Forward: 5’-TGCTGTCTCCATGTTTGATGTATCT-3’ 
Reverse: 5’-TCTCTGCTCCCCACCTCTAAGT-3’ 
Actin beta Actin β 
Forward: 5’-CTTCCTGGGCATGGAGTC-3’ 
Reverse: 5’-TGATCTTCATTGTGCTGGGT-3’ 
Glyceraldehyde 3-phosphate 
dehydrogenase 
GAPDH 
Forward: 5’-GTCGGAGTCAACGGATTTG-3’ 
Reverse: 5’-TGGGTGGAATCATATTGGAA-3’ 
Bone morphogenetic protein receptor 
type 1a 
BMPR1A 
Forward: 5’-ACTGCCCCCTGTTGTCATAG-3’ 
Reverse: 5’-AATGAGCAAAACCAGCCATC-3’ 
Fibronectin FN1 
Forward: 5’-AGTGGACACCACCCAATGTT-3’ 
Reverse: 5’-TTCATTGGTCCGGTCTTCTC-3’ 
 
RT-qPCRs were performed using SsoFastTM EvaGreen® Supermix with the CFX96 Touch real-time PCR 
detection system and CFX Manager software (version 3.1). The RT-qPCR cocktail was prepared 
according to Table 14. The thermal cycling conditions consisted of an initial denaturation at 95 °C for 3 
min, followed by 40 of the following additional cycles: 20 s denaturation at 95 °C, 20 s annealing at 60 °C 
and 30 s elongation at 75 °C. A melting curve step (95 °C for 30 s and heating from 65 to 95 °C in 0.5 °C 
increments of 5 s) was set to confirm the melting temperature (Tm) of the PCR products. No-treatment 
controls (NTC, only primer) were performed to exclude reaction contamination and primer dimerisation. 
Table 14 Composition of the RT-qPCR cocktail. 
Name Amount (μL) 
Ssofast supermix  5 
Forward primer  0.5 
Reverse primer  0.5 
cDNA  0.625 
Purified H2O 9.0 
Total final volume  10 
 
The quantification of gene expression was performed by the 2(-Delta CT) method (ΔΔCt) and reported 
as the fold difference in comparison to the internal controls and the control samples (set to 1). 
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4.9 ALP activity 
4.9.1 Materials 
Table 15 Materials and equipment for the ALP assay. 
Chemical Abbreviation Supplier 
QuantichromeTM alkaline phosphatase assay 
kit 
ALP kit 
BioAsssay Systems, Hayward, 
USA 
Sunrise™ microplate reader 
Microplate 
reader 
Tecan, Männedorf, Switzerland 
4.9.2 The principle and procedure 
The ALP, also known as tissue non-specific alkaline phosphatase (TNAP), is an ubiquitous enzyme in 
numerous tissues such as liver, kidney and bone. The quantification of ALP can indicate bone formation 
or mineralisation. ALP catalyses the hydrolysis of phosphate esters and produces both organic radicals 
and inorganic phosphate. For instance, p-nitrophenyl phosphate (pNPP) can be hydrolysed by ALP to 
produce a yellow product, which has an absorbance peak at 405 nm; the rate of production was directly 
proportional to the enzyme activity. Thus, ALP activity can be quantified via measuring the optical density 
of p-nitrophenol.  
HUCPV cell monocultures were seeded as 20,000 cells per well in 24-well plates. Direct-contact and 
transwell cocultures were seeded as described in the “Coculture system” section. All the groups were 
cultured in Mg degradation products or α-MEM-complete medium (as control) at 37 °C in 20 or 5% O2. 
On Days 1, 4 and 7, the supernatant was collected and stored at -80 °C for further assays. The variation 
in results induced by proliferation was normalised by the DNA concentration of HUCPV cells. DNA from 
the direct-contact coculture of HUCPV cells was calculated by from the flow cytometry and DNA 
quantification results. 
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4.10 ARS staining 
4.10.1 Materials 
Table 16 Materials and equipment for ARS staining 
Name Abbreviation Supplier 
Alizarin Red S ARS 
Sigma-Aldrich, Munich, 
Germany 
Nikon inverted microscope system, Ti-
S/L100 
Inverted 
microscope 
Nikon, Minato, Japan 
Sunrise™ microplate reader Microplate reader Tecan, Männedorf, Switzerland 
4.10.2 Procedures 
Alizarin Red S (ARS) is an anthraquinone dye that can react with both pure and ionic Ca to form Alizarin 
Red S-Ca precipitates with sulfonic acid and/or OH groups124. Alizarin Red S has been applied in many 
studies related to bone growth and calcium deposition - mineralisation (i.e., hydroxyapatite [a form of 
Ca10(PO4)6(OH)2]) in mesenchymal stem cells124. HUCPV cells were seeded as 20,000 cells per well in 
24-well plates as a monoculture. All mono- and cocultures were grown at 37 °C in 20% and 5% O2 in 
Mg degradation products or α-MEM medium (as control). On days 1, 4 and 7, ARS staining was 
performed, and the staining pattern was visualised by inverted microscopy.  
4.11 Enzyme-linked immunosorbent assay (ELISA) 
ELISA (enzyme-linked immunosorbent assay) is a colorimetric assay reaction designed for quantifying 
a ligand (commonly a protein). Here, sandwich ELISA was performed to quantify cytokines. The principle 
of sandwich ELISA is introduced in Appendix (Fig. S3). 
4.11.1 Materials 
The following solutions were prepared based on Table 17:  
 Wash buffer: 0.05% (v/v) Tween® 20 in PBS, pH 7.3, adjusted with 20% (v/v) HCl 
 Block buffer: 1% BSA in PBS, pH 7.3, 0.2 μm filtered 
 Substrate solution: 1:1 mix of H2O2 and TMB 
 Stop solution: 2 N H2SO4 
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 Capture antibody solution: reconstitute with no-protein PBS (the lyophilised antibody with epitope 
responding to the antigen of interest) 
 Detection antibody: was reconstituted in reagent diluent (biotinylated primary antibodies that 
respond to antigens with another epitope comparable to that of capture antibody) 
 Streptavidin-HRP:  was reconstituted in reagent diluent (secondary antibodies conjugated with and 
responsive to primary antibodies) 
Table 17 Materials and kits for ELISA  
Content Name Supplier 
Human FGF basic DuoSet® ELISA FGFb 
R&D Systems, Abingdon, UK 
Human IL-8/CXCL8 DuoSet® ELISA IL8 
Human CCL2/MCP-1 DuoSet® ELISA CCL2 
Human Total MMP-13 DuoSet® ELISA MMP13 
Human TIMP-1 DuoSet® ELISA TIMP1 
Human eNOS DuoSet® ELISA eNOS/NOS3 
Human VEGFA DuoSet® ELISA VEGFA 
Human PDGF-AA DuoSet® ELISA PDGFaa 
Human TGFβeta 1 DuoSet® ELISA TGFβ1 
Stabilised hydrogen peroxide (H2O2), stabilised 
with tetramethylbenzidine (TMB) 
Substrate 
solution 
Plate sealer Sealers 
A comprehensive collection of reagents and 
plates 
Reagent buffer 
Phosphate-buffered saline buffer PBS 
Thermo Scientific – Fisher Scientific 
GmbH, Langenselbold, Germany 
Nalgene syringe filter, sterile, SFCA membrane, 
0.2 μm 
0.2 μm filter 
Microplate with clear polystyrene wells and flat 
bottom 
Nunc™ 96-well 
plate 
Polyethylene glycol sorbitan monolaurate Tween® 20 Sigma-Aldrich, Munich, Germany 
Bio-Plex Pro™ wash station Autowasher Bio-Rad Laboratories, Munich, Germany 
Sunrise™ microplate reader Plate reader Tecan, Männedorf, Switzerland 
4.11.2 Procedures 
1) Capture antibody solution (50 μL) was added on the polystyrene surface in 96-well plates for 12 h 
at room temperature (RT). 
2) The nonbinding antibody was washed 2 times with 150 μL of wash buffer by an autowasher using 
crosswise aspiration. 
3) The remaining nonspecific surface was blocked with 50 μL of block buffer for 1 h at RT. 
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4) Block buffer was washed 2 times with 150 μL of wash buffer by an autowasher using crosswise 
aspiration. 
5) Antigens (samples or standards) were bound with 50 μL of capture antibodies for 1 h at RT. 
Depending on the antigen concentration, samples were diluted to avoid results fall beyond the linear 
range of the standard curve. 
6) Unbound antigen was washed 2 times with 150 μL of wash buffer by an autowasher using crosswise 
aspiration. 
7) Detection antibodies (50 μL) were bound to antigens for 1 h at RT. 
8) Unbound detection antibodies were washed 2 times with 150 μL of wash buffer by an autowasher 
using crosswise aspiration. 
9) Streptavidin-HRP (50 μL, supplied in each ELISA kit) was added to detect antibodies for 20 min at 
RT with no direct light. 
10) Unbound streptavidin-HRP was washed 2 times with 150 μL of wash buffer by an autowasher using 
crosswise aspiration. 
11) Streptavidin-HRP was incubated for 20 min with 50 μL of substrate solution at RT with no direct 
light. 
12) The reaction was terminated with 25 μL of the stop solution. 
13) The plates were shaken thoroughly, and the optical density of each well was determined using a 
plate reader at 450 nm wavelength, with 540 nm as the reference wavelength. 
4.12 Wound healing assay  
The EC migration process involves the development of angiogenesis through the enzymatic degradation 
of the capillary basement membrane, endothelial cell (EC) proliferation and the directed migration of 
ECs (Fig. 3). More specifically, endothelial cell migration is a mechanically integrated molecular process 
that involves cell adhesion, signal transduction and cytoskeletal organisation.  
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To investigate cellular edge extension during the migration of HUVECs, a wound healing assay was 
performed to elucidate differences in the wound closure area influenced by magnesium degradation 
products compared to that influenced by hypoxia, as indicated in Fig. 7. Cells were maintained in ECGM-
complete medium until approaching 80% confluence to obtain more activated cells in the exponential 
growth phase113. To achieve more reproducible results, HUVECs were first starved in ECGM with 1% 
FBS to synchronise the cellular life cycle in the G0/G1 phase and increase the reproducibility of cell 
responses. Then, HUVECs were treated with 10 µg/mL of mitomycin C, which can inhibit proliferation 
via cross-linking double-stranded DNA at its aminoquinone group125. Additionally, because mitomycin C 
does not affect RNA and protein synthesis, cytokine secretion and gene regulation, e.g., chemoattractant, 
can be analysed further based on wound healing samples126. 
 
Fig. 7 Schematic of HUVEC wound healing. 
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4.12.1 Materials 
Table 18 Materials for the wound healing assay 
Name Abbreviation Supplier 
Endothelial cell growth medium with 1% 
FBS  
Low FBS 
ECGM 
PromoCell, Heidelberg  
Endothelial cell growth supplement ECGS kit PromoCell, Heidelberg 
LIVE/DEAD viability kit for mammalian 
cells 
Calcein AM 
Thermo Scientific – Fisher Scientific GmbH, 
Langenselbold, Germany 
Trypsin-EDTA (0.05%), phenol red Trypsin 
Thermo Scientific – Fisher Scientific GmbH, 
Langenselbold, Germany 
Mitomycin C from Streptomyces Mitomycin C Sigma-Aldrich, Munich, Germany 
Costar® TC-treated multiple-well plates 24-Well plate Sigma-Aldrich, Munich, Germany 
Eppendorf® epT.IPS standard pipette 
tips, 1 mL 
1 mL Pipette 
tip 
Sigma-Aldrich, Munich, Germany 
Eclipse Ti-S inverted microscope system 
Inverted 
microscope 
Nikon, Minato, Japan 
Image processing and analysis in java, 
version 1.51b 
ImageJ National Institutes of Health, Bethesda, USA 
4.12.2 Procedures 
HUVECs were seeded in 24-well plates and cultured until reaching 80% confluence. 
1) Day 0: The HUVEC monolayer was starved in ECGM-complete medium without extra FBS for 24 h.  
2) Day 1: The monolayer of HUVECs was treated with 10 µg/mL of mitomycin C for 2 h. Wounds were 
produced using a standard 1 mL pipette tip on the cell monolayer. Pictures were acquired at 0 h 
with an inverted microscope as basic values (T0). Wounds were cultured in Mg degradation 
products under 20 and 5% O2 for 24 h. 
3) Day 2: Wounds were observed at 24 h, when pictures were acquired with an inverted microscope 
to represent the migration results (T24). The wound healing closure was calculated from the 
difference in scratch between T0 and T24 using ImageJ with the MRI plugin.  
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4.13 Tube formation assay 
An adapted thin-layer assay (TLA)114 was applied, as indicated in Fig. 8, to acquire RNA extract and 
images more easily and economically. TLAs do not need high-resolution/single-cell microscopy for 
image acquisition or matrix digestion with dispase for extracting mRNA but retain their performance for 
anchoring and differentiating HUVECs114. To preclude potential interference between cell and matrix, 
the basement membrane matrix was free of LDEV and reduced in growth factor. The density of cell 
seeding is a determinant factor since subconfluent density can ensure a monolayer to re-establish the 
tube reorganisation127–130. After plating, HUVECs were adhered, permitting their migration by 
mechanical forces to the ECM coating. The adhered cells created paths where cells migrated and 
ultimately formed capillary-like structures. These capillary structures were quantified by their number 
and length as well as the area of cell cords and hollow lumens in microscope images. The observations 
and supernatant collection were performed within 6 h (decided by section 5.2), since the interconnected 
network would thereafter diminish by low-cell-density-induced apoptosis. Since non-endothelial cell 
types also demonstrate tube formation111, this assay was only performed with HUVECs in monoculture 
and transwell coculture. 
 
Fig. 8 Schematic of HUVEC tube formation. 
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4.13.1 Materials 
Table 19 Materials for tube formation assay. 
Name Abbreviation Supplier 
Endothelial cell growth medium with 1% FBS (low FBS 
ECGM) 
Low FBS 
ECGM 
PromoCell, Heidelberg, Germany  
Endothelial cell growth supplement ECGS kit PromoCell, Heidelberg, Germany 
Minimum essential medium, Eagle-alpha modification α-MEM 
Fisher Scientific GmbH, Schwerte, 
Germany 
LIVE/DEAD viability/cytotoxicity kit for mammalian 
cells 
Calcein AM 
Thermo Scientific – Fisher Scientific 
GmbH, Langenselbold, Germany 
Geltrex® LDEV-free reduced growth factor basement 
membrane matrix 
Matrix 
Thermo Scientific – Fisher Scientific 
GmbH, Langenselbold, Germany 
Trypsin-EDTA (0.05%), phenol red Trypsin 
Thermo Scientific – Fisher Scientific 
GmbH, Langenselbold, Germany 
Corning® Costar® TC-treated multiple-well plates 24-well plate Sigma-Aldrich, Munich, Germany 
Eppendorf® Combitips Advanced® pipette tips, quality 
grade, 0.5 mL 
Combitip Sigma-Aldrich, Munich, Germany 
Eclipse Ti-S inverted microscope system, Ti-S/L100 
Inverted 
microscope 
Nikon, Minato, Japan 
Image processing and analysis in java, version 1.51b ImageJ National Institutes of Health, 
Bethesda, USA 
4.13.2 Procedures 
1) Day 0: matrix was thawed on ice at 4 ℃ overnight. 
2) Day 1: 10 μL of matrix was spread evenly within 30 s in each well of 24-well plates with the insert 
end of a combitip while avoiding any the production of bubbles in the monolayer (bubbles can disrupt 
tube formation). During the whole experiment, the matrix was on ice to avoid its degradation. 
HUVECs were seeded as 40,000 cells per well with α-MEM-complete medium in 24-well plates. 
After 30 min of cell adhesion, culture medium was replaced with Mg degradation products or control 
medium accordingly. 
3) Day 1+6 h: after supernatant collection, cells were stained with diluted Calcein AM (1:2500 (v/v) in 
PBS) and incubated in 20% or 5% O2 for 30 min. PBS was added, and pictures of 3 different fields 
of each sample was taken under an inverted microscope. 
4) Images were analysed using ImageJ (1.51b, National Institutes of Health, USA) with the 
Angiogenesis Analyzer Plugin. 
Materials and methods 
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4.14 Statistical analysis 
The results of section 5.1 (immunophenotyping) and section 5.5 (ALP activity of HUCPV cell 
monoculture) were collected from two technical replicates of three independent experiments (n=3). The 
results of section 5.3 were collected from two independent experiments with two replicates of two donors 
(n=4). Other results were acquired from two technical replicates of two independent experiments from 
three donors (n=6). The results are presented as the average and standard deviation (SD). If not 
specifically mentioned, the data were analysed with either one-way ANOVA or one-way ANOVA after 
ranking based on the distribution of data via SigmaPlot 13.0 (version 13.0; Systat Software GmbH, 
Erkrath, Germany). The following post hoc multiple comparisons were based on the Dunnett's or 
Student-Newman-Keuls (SNK) test (α=0.05) when equal variance was assumed or not, respectively. 
For RT-qPCR, to detect differential expression, a t-test (α=0.05, P≤0.05) was employed, and differential 
expression was directly calculated using CFX manager software (version 3.1; Bio-Rad, Munich, 
Germany). 
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5 Results 
5.1 The isolation, validation and differentiation potential of existing HUCPV 
and HUVEC 
According to the cell distribution of the umbilical cord, HUCPV cells were isolated from the perivascular 
WJ covering the artery surface. Additionally, HUVECs were extracted from the inner lumen layer of the 
vein using collagenase type IA. To ensure purity and the osteogenesis and angiogenesis potential, 
HUCPV cells and HUVECs were labelled with antibodies or isotypes, as listed in Table 8. Isolated 
HUCPV cells and HUVECs show typical “fibroblast” and “cobblestone” morphology (Figs. 9a and 9b). 
In HUCPV cells, positive CD 105 and CD 90 markers suggest a highly purified population, and 
endothelial contamination is excluded by a negative CD 31 result, presented in Fig. 9c. The high positive 
CD 105 and CD 31 values indicate purified HUVECs, for which hematopoietic contamination is excluded 
by the negative result for CD 45 (Fig. 9d).   
Fig. 9 HUCPV cell and HUVEC characterisation: a) HUCPV cell fibroblastic morphology, b) HUVEC 
cobblestone morphology, and summaries of the surface markers for (c) HUCPV cells and HUVECs (d). 
Statistical significance was tested by ANOVA with Dunnett's test (α=0.05, ***P≤0.001). 
Results 
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Method 1, 2 and 3 contain different osteogenic components to induce the osteogenesis of isolated 
HUCPV cells91, 110. As shown in Fig. 10, the DNA content on day 7 was significantly increased by method 
2. On day 14, the DNA content was decreased by method 1 but significantly increased by method 2. On 
day 21, the DNA content for method 1 was significantly reduced. Methods 2 and 3 almost induced less 
ALP activity at all three timepoints. The ALP activity induced by method 1 was significantly higher on 
days 14 and 21. The mineralisation (Fig. 11) indicated by ARS staining for all treatments, especially for 
methods 2 and 3, was obviously higher on days 14 and 21. The tube formation by HUVECs (Fig. 12) 
suggested that the observation window should be 6 h. 
 
 
Fig. 10 DNA content and ALP activity of HUCPV cells during the 21 days of differentiation: (a) DNA, (b) 
ALP. The asterisks indicate significance by ANOVA (α=0.05, *P≤0.05, **P≤0.01). 
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Fig. 11 ARS staining of HUCPV cells for 21 days. The scale represents 100 μm. The HUCPV cells 
were seeded as 5,000 cells/cm2 in different media containing osteogenic chemicals. 
Fig. 12 Tube formation of isolated HUVEC. HUVEC were seed as 50,000 cells/cm2 in 24-well-plate 
and cultured for 6 and 24 h. Tubes were stained with Calcein AM in PBS and observed under inverted 
microscope. 
According to the CD 105+, CD 90+, CD 54- and CD 31- expression levels and the fibroblastic shape of 
the HUCPV cells, their isolation from human umbilical cord vein can reliably produce MSCs without 
endothelial contamination for further study. The ARS staining and the ALP and proliferation levels 
induced by the different osteogenic chemicals indicate the osteogenesis potential of isolated HUCPV 
cells. The typical morphology and the CD 105+, CD 31+ and CD 45- markers of the isolated HUVECs 
suggest that collagenase digestion in the vein lumen of human umbilical cord can dependably produce 
ECs without blood contamination. Furthermore, the capillary structure formed by the tube formation 
assay suggests the differentiation of isolated HUVECs.  
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5.2 Optimisation and validation of the coculture system 
The α-MEM- and ECGM-complete media were originally used as culture media for the HUCPV cells 
and HUVECs, respectively. α-MEM and ECGM contain 0.814 and 10mM background Mg. The possible 
influence of α-MEM on EC growth induction should be measured. The proliferation and metabolism of 
HUCPV cells and HUVECs when cultured in α-MEM and ECGM are presented in Figs. 13 and 14. The 
HUCPV cells were incubated in α-MEM-complete medium and ECGM-complete medium for 9 days. On 
days 3, 6 and 9, the DNA concentration was measured by the fluorescence of bisbenzimide. On days 3, 
6 and 9, the metabolic activity was quantified via culturing cells in WST-1 solution (1:10 v/v, water-soluble 
tetrazolium salt-1) supplemented with the corresponding medium for 30 min.  
During the expansion of direct-contact coculture, HUCPV cells and HUVECs will contact each other and 
compete for the bottom surface of the cell culture plate or flask. According to the HUCPV cell growth in 
α-MEM and observation during the direct-contact coculture trial under bright field, HUPCV cells seem 
to proliferate faster and occupy more culture area compared to HUVECs. Moreover, the 7-days-
coculture was chosen because proliferation and metabolism were significantly decreased in α-MEM on 
day 9 (Figs. 13 and 14). Thus, to assure the consistent existence of HUCPV cells and HUVECs up to 7 
days, the direct coculture was simultaneously labelled with CD 90 and CD 31 in flow cytometry. Single 
staining with CD 90 and CD 31 was applied respectively for fluorescence compensation of the analysis 
results. The positive percentage of CD 90 and CD 31 represents HUCPV cells and HUVECs, 
respectively, in Fig. 15. 
Fig. 13 DNA content of HUCPV cells and HUVECs in ECGM- and α-MEM-complete media by 
bisbenzimide. The asterisk indicates significance by t test (α=0.05, *P≤0.05, **P≤0.01).  
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Fig. 14 Metabolic activity of HUCPV cells and HUVECs in ECGM- and α-MEM-complete media by WST-
1 assay. The asterisk indicates significance by t test (α=0.05, *P≤0.05, **P≤0.01).  
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 15 The quantification of HUCPV cells and HUVECs in the total population of direct-contact 
cocultures. To suggest the percentage of HUCPV cells and HUVEC, direct-contact cocultures were 
stained with CD 90 and CD 31, respectively, and investigated through flow cytometry. 
The results in the “medium test” section indicate the possible growth of both HUCPV cells and HUVECs 
in α-MEM for at least 9 days. The results (Figs. 13 and 14) also suggest that the growth of HUCPV cells 
and HUVECs cocultured in transwell with α-MEM for up to 9 days can be possible. The possible 
influence of background Mg in ECGM on cell growth should be investigated because plans exist to study 
a low dose of Mg for its proven effect on ECs70. Therefore, considering the heightened metabolism in α-
MEM and the potential effect of a low dose of Mg70, α-MEM was hereafter applied as the coculture 
medium. The existence of HUCPV cells and HUVECs in direct-contact cocultures was assured by the 
expression of CD 90+ and CD 31+ for at least 7 days.   
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5.3 Magnesium degradation products and hypoxia influenced the HUVEC 
angiogenesis stage 
5.3.1 Proliferation of HUVECs indicated by DNA quantification 
Proliferation was assessed by the DNA content. No significant change in the DNA content was measured 
with Mg at 20% O2. However, under 5% O2, HUVECs cultured with 4 and 8 mM Mg degradation products 
exhibited an increased DNA content compared to that of the control (Fig. 16a). According to multiple 
comparison testing (Fig. 16b), the 4 mM and 8 mM Mg treatments under hypoxia had a higher DNA 
content than those measured at different Mg concentrations under 20% O2 (except 4 mM 5% vs Ctr 
20%).  
Fig. 16 Proliferation of HUVECs indicated by DNA contents: (a) significance between treatments was 
tested by ANOVA and indicated by an asterisk (*P≤0.05 and ***P≤0.001) and (b) post hoc multiple 
comparisons between each treatment. A solid dot represents a significant difference. 
5.3.2 Metabolism measured via WST-1 assay and rhodamine 123  
The tetrazolium salt WST-1 (4-[3-(4-iodophenyl)-2-(4-nitrophenyl)-2H-5-tetrazolio]-1,3-benzene 
disulfonate) can be cleaved into formazan dye, which can in turn quantitatively represent the metabolic 
activity of cells. Normalising the results of the WST-1 and R123 assays with DNA content, i.e., cell 
number, enables a comparison of the influence of magnesium degradation products on HUVEC 
metabolism. Under 5% O2, statistically significant decreases can be seen at the 4 and 8 mM Mg levels 
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compared to the control and between the 2 and 8 mM treatments (Fig. 17).  
Fig. 17 Metabolic activity of HUVEC measured by the WST-1 assay: (a) significance between treatments 
was tested by ANOVA and indicated by an asterisk (**P≤0.01 and ***P≤0.001) and (b) post hoc multiple 
comparisons between each treatment. The solid dots represent significant differences. 
Mitochondrial membrane potential (Δψm) indicated by rhodamine 123  
The fluorescence of rhodamine 123 staining can indicate the change of Δψm, which relates to the 
metabolism of HUVECs. To measure the influence of Mg degradation products and the O2 content on 
mitochondrial membrane energisation, the mitochondrial membrane potential gradient was measured. 
Adenosine triphosphate (ATP) synthesis by F0F1ATPase during cellular respiration originates from an 
electrochemical gradient created by a difference in proton (H+) concentration across the mitochondrial 
membrane (i.e., a potential)131. The quenching of R123 fluorescence is induced by inhibiting 
mitochondrial energisation; therefore, the measurement of ΔΨM is possible because ΔΨM is 
proportional to the fluorescence decay rate132. R123 is a fluorescent cationic dye capable of binding to 
mitochondrial and other plasma membranes. Digitonin can increase the sensitivity of R123 probes by 
permeabilising the cell plasma membrane, allowing access to the inner membrane122. Antimycin A, an 
inhibitor of complex III in the respiratory chain, can rapidly collapse the energy-linked absorbance 133. 
Therefore, the combination of digitonin, R123 and antimycin A permits an assessment of mitochondrial 
energisation in intact cells and the exclusion of non-mitochondrial staining by subtracting the 
fluorescence after antimycin A treatment (Fig. 18a). HUVECs treated with 2 and 4 mM Mg under 20% 
O2 showed significantly increased R123 retention. However, under 5% O2, all the Mg doses markedly 
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decreased Δψm (Fig. 18b). Multiple comparison tests (Fig. 18c) indicated a role for hypoxia compared 
with normoxia (20% O2) in increasing ΔΨM. 
Fig. 18 Mitochondrial membrane potential of HUVEC measured by R123 fluorescence quenching in the 
presence of Mg degradation products: (a) principles and procedural overview of ΔΨM tests, (b) 
significance between treatments tested by ANOVA indicated by an asterisk (*P≤0.05, **P≤0.01 and 
***P≤0.001) and (c) post hoc multiple comparisons between each treatment. Solid dots represent a 
significant difference. 
5.3.3 Migration ability was increased by Mg in normoxia 
The wound closure was calculated from the difference in scratch areas between 0 and 24 h to assess 
the influence of Mg on the cell migration ability. Under 5% O2 and compared to a 5% control, the Mg 
degradation products did not influence the closure area or cell migration (Fig. 19). However, cell 
migration was increased with the Mg products at 20% O2 (significantly with 2 mM Mg compared to the 
20% control). Even with a bell-shaped curve, migration may be increased at a low concentration of Mg 
extract and decreased at high concentration (Fig. 19a). 
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Fig. 19 Wound healing closure of HUVECs in the presence of Mg degradation products under hypoxia 
(5% O2) or normoxia (20% O2). (a) Pictures were acquired with an inverted microscope at 0 and 24 h, 
and the wound closure area was analysed with ImageJ. (b) Values represent the no-cell-area difference 
between 24 and 0 h, further normalised to relative controls. Significance between treatments was tested 
by ANOVA and indicated by an asterisk (*P≤0.05). (c) Post hoc multiple comparisons were performed 
between each treatment, with solid dots representing a significant difference (P≤0.05). 
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5.3.4 Tube formation was decreased by Mg in normoxia 
An obvious reduction in the total length of tubes and the number of branches at 4 and 8 mM Mg (Fig. 
20a) was observed under 20% O2 after 6 h. However, under 5% O2, no significant change occurred (Fig. 
20a). Post hoc tests did not indicate significant effects induced by Mg between the 20 and 5% O2 levels 
(Figs. 20b and 20c). 
Fig. 20 Tube formation of HUVECs in magnesium degradation products. After 6 h, tubes were stained 
with calcein AM, and images were taken with an inverted microscope (a). With ImageJ and the 
angiogenesis analyser plugin, the total length of tubes (b) and the number of branches (c) were 
calculated. Significance between treatments was tested by ANOVA and indicated by an asterisk 
(*P≤0.05 and **P≤0.01). 
5.3.5 Gene regulation during migration and tube formation was influenced by Mg and 
hypoxia 
To explore the gene regulation potentially influenced by Mg degradation products and hypoxia during 
the migration of HUVECs, specific gene expression levels were studied. Significantly regulated genes 
are presented in Table 20. Under 5% O2, most of the selected genes were downregulated, but not in a 
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dose-dependent manner. These results are in accordance with the phenotypic observations during 
wound healing (i.e., no effect observed under hypoxia and increased Mg extract concentrations). Under 
20% O2, fewer genes were regulated. However, the bell shape previously observed in wound healing 
can be related to certain gene expression levels. Indeed, some genes (e.g., those coding for vascular 
endothelial growth factor B isoform (VEGFB186) and interleukin 8 (IL8 or chemokine (C-X-C motif) 
ligand 8, CXCL8)) exhibited an increased and then a decreased expression as the Mg concentrations 
increased. Other genes, such as those coding for angiogenin (ANG) and tissue inhibitors of 
metalloproteinase 1 (TIMP1s), were upregulated only at 2 mM. To produce an exhaustive results 
description and highlight potential relationships, regulated genes were classified into 6 groups. 
i. Cell surface and cytoskeleton organisation. Under 20% O2, ANG and ezrin (EZR) were 
upregulated in 2 mM Mg. Vascular cell adhesion molecule 1 (VCAM1) was upregulated by 4 mM 
Mg. VEGFB186 and vascular endothelial growth factor receptor 1 (FLT1) were upregulated by 2 
and 4 mM Mg but downregulated by 8 mM Mg. Vascular endothelial growth factor receptor 2 (KDR) 
was upregulated in 2 and 4 mM Mg. Transmembrane 4 (CD9) was upregulated and 
downregulated in 2 and 8 mM Mg, respectively. Under 5% O2, all these genes were increasingly 
downregulated from 2 to 8 mM Mg. 
ii. Adhesion. Integrin subunit alpha 2 (ITGA2) and integrin subunit alpha M (ITGAM) was 
upregulated in 2 mM but ITGA2 was also downregulated in 8 mM at 20% O2. Under hypoxia, 
ITGA2 was downregulated in 2 to 8 mM and ITGAM was downregulated in 2 and 4 mM. 
iii. Migration and precondition for vessels. At 20% O2, IL8 was upregulated in 2 and 4 mM Mg 
while downregulated in 8 mM. Matrix metallopeptidase 13 (MMP13) was upregulated in 2 and 4 
mM Mg. TIMP1 was upregulated in 2 mM Mg. Under hypoxia, IL8, MMP13 and TIMP1 were all 
downregulated under the influence of 2 to 8 mM Mg. 
iv. HUVEC differentiation and hypoxia sensors. Basic fibroblast growth factor (FGFb), hypoxia-
inducible factor 1 alpha subunit (HIF1A) and Interferon gamma (IFNγ) were upregulated in 2 mM 
at 20% O2; however, these factors were downregulated by Mg at 5% O2. HIF2A was 
downregulated in 8 mM Mg under 20% O2 and also downregulated in 2 to 8 mM Mg under hypoxia. 
The IFNγ was upregulated in 2 mM at 20% O2 while downregulated in 2 and 4 mM Mg in 5% O2.  
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v. Ca2+ and Mg2+ flux, cell mobility and blood vessel diameter. Ca-activated neutral protease 1 
(CAPN1) was observed to be upregulated at 20% O2 in 2 mM Mg but then to be markedly 
downregulated in up to 8 mM Mg under 5% O2. Claudin 16 (CLD16) was significantly 
downregulated under hypoxia. 
vi. Vascularity protection and adaptive effect. Nitric oxide synthase (NOS2) was upregulated 
under 20% O2 while significantly downregulated in 2 and 4 mM Mg under 5% O2. 
The regulation of selected genes influenced during tube formation by Mg degradation products and O2 
content was investigated. Specific targets were tested and the significant changes were present in Table 
20. During tube formation, only ANG and ITGA3 were upregulated by Mg degradation products under 
20% O2; however, 11 genes were downregulated. Under hypoxia, downregulation was tempered, and 
four genes were even upregulated. Only MMP13 was downregulated in 5% O2. In addition, the highly 
regulated genes were classified into 6 classes. 
i. Cell surface and cytoskeleton organisation. No obvious regulation of ANG was observed under 
5% O2, but significant upregulation occurred under 20% O2 in 2 mM Mg. VEGFB186 was 
downregulated under 20% O2 in 4 and 8 mM but upregulated under 5% O2 in 8 mM Mg. Both FLT1 
and KDR were downregulated under 20% O2 in 4 and 8 mM concentrations while upregulated in 2 
mM Mg under hypoxia. No significant regulation of CD9 and EZR was observed under hypoxia. 
CD9 was downregulated under 20% O2 in 4 and 8 mM Mg. EZR was downregulated in 4 Mm Mg 
under 20% O2.  
ii. Adhesion. Mg extract did not influence the expression of ITGA2 or ITGAM under either 20 or 5% 
O2. ITGA3 was upregulated in 2 mM Mg under 20%. 
iii. Migration and precondition for vessels. IL8 and MMP13 were downregulated by 4 mM Mg 
degradation products in 20 and 5% O2. TIMP1 was strongly downregulated in 4 and 8 mM Mg 
degradation products. 
iv. HUVEC differentiation and hypoxia sensors. Both HIF1A and HIF2A expression were 
upregulated by 2 mM Mg but downregulated in 4 mM Mg under 20% O2. However, HIF1A was 
downregulated in 4 mM Mg and upregulated in 8 mM Mg under hypoxia. IFNγ was downregulated 
in 4 mM Mg under 20% O2.  
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v. Ca2+ and Mg2+ flux, cell mobility and blood vessel diameter. CAPN1 and CLD16 were 
downregulated in 4 and 8 mM Mg under 20% O2. 
vi. Vascularity protection and adaptive effect. NOS2 was downregulated in 4 and 8 mM Mg under 
20% O2.  
Table 20 Gene expression changes with Mg degradation product concentration and hypoxia. Slashes 
“/” indicate non-significant regulation. Asterisks represent *P≤0.05 or **P≤0.01. 
 
 
 
 
 
Function Name 
Mg 
content 
(mM) 
Wound healing Tube formation 
5% O2 20% O2 5% O2 20% O2 
Cell surface 
organisation; 
cytoskeleton 
activity 
Angiogenin (ANG) 
2 -3.033** +1.966** / +4.283** 
4 -4.200** / / / 
8 -4.306** / / / 
Vascular cell adhesion 
molecule 1 (VCAM1) 
2 -2.393** / / / 
4 -2.750** +2.220** / / 
8 -2.002** / / / 
Vascular endothelial growth 
factor B isoform (VEGFB186) 
2 -3.626** +1.931** / / 
4 -5.509** +1.560** / -1.838** 
8 -4.189** -1.503** +2.402* -1.863** 
Vascular endothelial growth 
factor receptor 1 (FLT1) 
2 -3.293** +1.909** +2.476* / 
4 -4.757** +1.581** / -2.974* 
8 -3.766** -1.382** +2.521* -2.027* 
Vascular endothelial growth 
factor receptor 2 (KDR) 
2 -3.647** +1.819** +2.373* / 
4 -4.892** +1.445** / -3.997** 
8 -3.998** / +2.322* -2.229** 
Transmembrane 4 (CD9) 
2 -3.616** +1.851** / / 
4 -4.890** / / -2.298* 
8 -4.249** -1.501* / -2.750* 
Ezrin (EZR) 
2 -3.975** +2.067** / / 
4 -5.629** / / -3.953 
8 -2.771** / / / 
Adhesion 
Integrin subunit alpha 2 
(ITGA2) 
2 -3.330** +1.681** / / 
4 -5.707** / / / 
8 -4.235** -1.414** / / 
Integrin subunit alpha 3 
(ITGA3) 
2 / / / +2.028* 
4 / / / / 
8 / / / / 
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Table 20 (Continued) 
 
 
 
 
 
Function Name 
Mg 
content 
(mM) 
Wound healing Tube formation 
5% O2 20% O2 5% O2 20% O2 
Adhesion 
Integrin subunit alpha M 
(ITGAM) 
2 -2.810** +3.138* / / 
4 -2.935** / / / 
8 / / / / 
Chemotaxis; 
collagen 
degradation 
C-X-C motif ligand 8 (CXCL8, 
IL8) 
2 -3.546** +1.893* / / 
4 -4.749** +1.523* / -1.934* 
8 -3.182** -1.854** / / 
Matrix metallopeptidase 13 
(MMP13) 
2 -5.321** +2.706** / / 
4 -6.037** +2.722* -2.554* / 
8 -4.378** / / / 
Tissue inhibitors of 
metalloproteinase 1 (TIMP1) 
2 -4.003** +1.343** / / 
4 -5.209** / / -2.943** 
8 -3.299** / / -1.867* 
Regulation of 
HUVECs 
differentiation 
Hypoxia-inducible factor 1 
alpha (HIF1A) 
2 -2.536** +1.448* / +2.271* 
4 -2.618** / -1.465* -2.260* 
8 -2.027** -1.392* +1.904** / 
Hypoxia-inducible factor 2 
alpha (HIF2A, EPAS1) 
2 -2.825** / / +2.405** 
4 -3.175** / / -2.335** 
8 -2.321** -1.977** / / 
Basic fibroblast growth factor 
(FGFb) 
2 -2.683** +1.861* / / 
4 -4.040** / / / 
8 -3.716** -1.630* / / 
Interferon gamma (IFNγ) 
2 -2.611** +2.250** / / 
4 -3.312** / / -2.274* 
8 / / / / 
Mg2+ and 
Ca2+ flux; 
blood vessel 
diameter 
Calpain 1 (CAPN1) 
2 -3.067** +1.626* / / 
4 -5.346** / / -4.118* 
8 -3.975** -1.962** / -3.485** 
Claudin 16 (CLD16) 
2 / / / / 
4 -3.773** / / -3.605** 
8 -2.560** / / -1.990* 
Vascularity 
protection and 
adaptivity 
Nitric oxide synthase 2 (NOS2) 
2 -4.614** +2.974** / / 
4 -8.479** -3.697** / -3.697** 
8 / -5.965* / -5.965* 
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5.3.6 VEGFA and VEGFB levels during migration and tube formation indicated by 
ELISA 
To determine whether the influence of Mg and oxygen conditions on the capillary formation and cell 
migration is mediated through VEGFA and/or VEGFB, two angiogenic factors from the VEGF family, 
their concentrations were quantified in the supernatant from the wound healing and tube formation 
experiments at their endpoints: 6 and 24 h, respectively.  
For VEGFA in wound healing and tube formation, no differences were observed under hypoxia. However, 
under normoxia, a dose-dependent decrease was detected for VEGFA in wound healing (with 
statistically significant decreases for 8 mM Mg vs Ctr and 2 mM Mg). For tube formation, approximately 
the same level of statistically significant downregulated VEGFA was detected for all the Mg 
concentrations vs Ctr. During wound healing (Fig. 21c), a dose-dependent decrease and increase in 
VEGFB levels were observed for normoxia and hypoxia, respectively. Similar results were found for tube 
formation: a decreased VEGFB level in normoxia (20% O2), while all the VEGFB levels were upregulated 
in an (Mg) dose-dependent manner under hypoxia (with Ctr vs 4 mM and 8 mM showing statistically 
significant differences).  
Results 
 
57 
 
Fig. 21 VEGFA and VEGFB levels secreted in the wound healing (a and c, respectively) and tube 
formation (b and d, respectively) assays. An asterisk represents a significant difference between the Mg 
groups and controls with the same oxygen setting (*P≤0.05 and **P≤0.01) by ANOVA test. 
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5.4 Magnesium degradation products and hypoxia influenced the 
intermediate stage of HUCPV cells and HUVECs 
5.4.1 Proliferation of HUCPV cells and HUVECs in transwell coculture 
As indicated in Fig. 22a, the total DNA content increased on day 1 in an Mg-concentration-dependent 
manner. On days 4 and 7, this content increased compared to day 1 and remained relatively constant 
(except day 4 with 8 mM Mg). While analysing the HUCPV-HUVEC proportions, clearly enhanced 
HUVEC and deceased HUCPV cell proliferation (occurring in an Mg-concentration-dependent manner) 
was measured on day 1. On day 4, while the HUCPV cell content remained stable, a slight increase in 
HUCPV cells could be observed. On day 7, both cell types remained relatively constant. Under normoxia 
(Fig. 22b), the total DNA content was comparatively constant during the 7-day assay, while it slightly 
decreased with an increasing Mg concentration on all the measurement days. The HUCPV-HUVEC 
ratios stayed stable on days 1 and 7. However, on day 4, enhanced HUCPV and deceased HUVEC 
proliferation (occurring in an Mg-concentration-dependent manner) were measured.  
Fig. 22 DNA content and percentage of HUCPV cells and HUVECs in transwell coculture: DNA under 
5% (a) and 20% O2 (b) and cell percentage under 5% (c) and 20% O2 (d). Dark grey and black asterisks 
indicate the significance of HUVECs and HUCPV cells, respectively, in ANOVA tests (α=0.05, *P≤0.05). 
The DNA content was investigated by bisbenzimide fluorescence. Cell ratio was calculated by the DNA 
ratio between HUCPV cells and HUVECs. 
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5.4.2 Gene expression of HUCPV cells and HUVECs in 7-day-transwell coculture 
To simultaneously explore their gene regulation, HUVECs (insert) and HUCPV cells (cell well bottom) 
were separately cultured in transwells for 7 days. The gene regulation folds and significance are 
summarised in Table 21 and 22, respectively. On day 1, under hypoxia in HUCPV cells, only MMP13 
was up- (2 mM Mg) or downregulated (4 and 8 mM Mg). However, under normoxia, the bone 
morphogenetic protein 4 (BMP4), IL8, MMP13, PDGFA and TIMP1 expression levels were increased 
by up to 4 mM Mg (and at 8 mM, BMP4 and MMP13 were downregulated). On day 4, under hypoxia, 
BMP4, EPAS1/HIF2A, MMP13, OPG and PDGFA were upregulated under different Mg concentrations. 
However, these increased expression levels were instead downregulated under normoxia, (except 
MMP13 and PDGFA). COL1A1 was downregulated on day 4 with 4 or 8 mM Mg under both normoxia 
and hypoxia, while IL8 was only downregulated under hypoxia on day 4. On day 7, BMP4, IL8, MMP13, 
OPG and TIMP1 expression was decreased by 2 or 4 mM Mg under hypoxia. CCL2 was downregulated 
by 2 mM but upregulated by 8 mM Mg under hypoxia. Under normoxia, all the genes except OPG were 
downregulated by up to 8 mM Mg.  
On day 1, HUVEC, ANG, IL8, ITGA1, MMP13 and TIMP1 were all decreased under hypoxia by up to 8 
mM Mg. By contrast, KDR and VEGFB186 were downregulated by 2 and 4 mM Mg. Under normoxia, 
the expression on day 1 for ANG, IL8, ITGA1, KDR, MMP13, TIMP1 and VEGFB186 was not decreased 
from 4 mM Mg but was increased by 8 mM Mg. On day 4, EPAS1/HIF2A was upregulated by 4 mM Mg, 
while VEGFB186 was increased by 2 and 4 mM Mg but decreased by 8 mM Mg under hypoxia. However, 
under normoxia, ANG, CCL2, IL8, KDR, VEGFB186, EPAS1/HIF2A and MMP13 were all upregulated 
for HUVECs by 4 and 8 mM Mg. On day 7, only MMP13 was significantly regulated in hypoxia (increased 
by 2 mM but decreased by 4 and 8 mM Mg). Under normoxia, MMP13 and EPAS1/HIF2A were 
decreased by 2 or 4 mM Mg, while MMP13 expression was upregulated by 8 mM Mg. 
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Table 21 Summary of gene regulation in HUCPV cells during 7 days of non-contact or transwell coculture. 
The slash “/” means non-significant regulation. Positive and negative numbers mean up- and 
downregulation, respectively. Significance between treatments was analysed by t tests and is indicated 
by asterisks (α=0.05, *P≤0.05, **P≤0.01 and ***P≤0.001). 
Oxygen Day 
Mg 
(mM) 
Gene 
BMP4 CCL2 COL1A1 
EPAS1/ 
HIF2A 
IL8 MMP13 OPG PDGFA TIMP1 
5% 
1 
2 / / / / / 3.1* / / / 
4 / / / / / -1.4* / / / 
8 / / / / / -1.7* / / / 
4 
2 3.1** / / 8.6*** -1.0* 4.3* 2.4* 2.8* / 
4 / / -8.8*** 3.8*** -2.5* 4.2* / 2.7* / 
8 / / -3.7*** 7.7*** -1.7* / 1.8* 2.9* / 
7 
2 -1.9* -1.5*** / / -1.4* -2.3* -3.9** / -1.6** 
4 / / / / / -1.3* / / / 
8 / 1.6*** / / / / / / / 
20% 
1 
2 5.6** / / / 4.8* 3.1* / 5.2* 4.9* 
4 3.5** / / / / 3.3* / 2.9* 3.8* 
8 -3.3* / / / / -6.3* / / / 
4 
2 -2.1** / / / / -1.6* / / / 
4 / / -5.0*** / / 1.5* / -1.2* / 
8 / / / -2.1* / -2.1* / 1.1* / 
7 
2 / -1.2* / / / / / / / 
4 -3.3*** -1.6*** / -4.4*** / / / / / 
8 -7.8*** -5.6*** -6.5*** -12.5*** -4.1** -7.4** / -5.5** -4.9*** 
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Table 22 Summary of HUVEC gene regulation in 7 days of non-contact or transwell coculture. The slash 
“/” means non-significant regulation. Positive and negative numbers mean up- and downregulation, 
respectively. Significance between treatments was analysed by t tests and is indicated by asterisks 
(α=0.05, *P≤0.05, **P≤0.01 and ***P≤0.001). 
Oxygen Day 
Mg 
(mM) 
Gene 
ANG CCL2 
EPAS1 
/HIF2A 
IL8 ITGA1 KDR MMP13 TIMP1 VEGFB186 
5% 
1 
2 -6.4*** / / -3.7** -3.7*** -1.92* -3.8*** -4.1*** -2.2*** 
4 -3.7*** / / -5.9** -4.8*** -3.2** -4.7*** -3.5*** -1.6** 
8 -2.5*** / / -3.9** -3.3** / -2.5* -2.5*** / 
4 
2 / / / / / / / / 1.0* 
4 / / 1.9** / / / / / 1.1* 
8 / / / / / / / / -1.8* 
7 
2 / / / / / / 1.3* / / 
4 / / / / / / -1.1* / / 
8 / / / / / / -1.0* / / 
20% 
1 
2 -1.5* / / -2.6*** -1.7* -1.9*** -2.1* -2.7*** -1.9*** 
4 / / / / / / / / / 
8 2.1*** / / / 3.6** 1.9*** 3.1** 1.8*** 2.6*** 
4 
2 / / / / / / / / / 
4 2.2* 2.3* / 1.9* / 2.6*** / / 1.5* 
8 3.8** 4.0* 2.5*** 5.4* / 2.0** 20.8*** / 4.4** 
7 
2 / / -1.4* / / / -1.1* / / 
4 / / / / / / -1.0* / / 
8 / / / / / / 1.4* / / 
5.4.3 Cytokine levels in transwell coculture up to 7 days  
The levels of cytokines acting as regulators of migration, angiogenesis and osteogenesis were 
investigated using ELISA. The results (fold changes and significances compared to a relative control) 
for migratory cytokines (CCL2, IL8, MMP13 and TIMP1) and key regulators of angiogenesis and 
osteoblastogenesis (PDGFA, VEGFA, FGFb and eNOS) are summarised in Fig. 23 and Table 23. Under 
hypoxia, expression was high on day 1, decreased on day 4 and increased again on day 7 (except for 
eNOS and FGFb). On day 1 (except for PDGF), a decreased expression with increased Mg 
concentration was observed (statistically significant for VEGFA, FGFb, TIMP1, MMP13, IL8 and CCL2). 
On day 4, the cytokine levels remained rather low and constant independently of the Mg concentrations. 
On day 7, expression increased, and the inhibition from an increasing Mg concentration was no longer 
observed. Indeed, for eNOS, FGFb and CCL2, increased cytokine levels could be seen as the Mg 
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concentrations increased.  
Under normoxia, the overall decreased expression was not observed. By contrast, the expression 
remained rather constant (VEGFA, eNOS and FGFb) or increased on day 7 (e.g., PDGFA and CCL2). 
Furthermore, in certain cases (except for PDGF), increased Mg concentrations increased cytokine 
expression (e.g., a statistically significant increase for MM13 on day 1 comparing control vs 8 mM Mg).  
Fig. 23 Cytokine levels in the supernatant after 7 days of non-contact or transwell coculture. The control 
and 2, 4, and 8 mM Mg treatments are indicated in white, grey, dark grey and black, respectively. (a) 
VEGFA, (b) eNOS, (c) PDGFA, (d) FGFb, (e) TIMP1, (f) MMP13, (g) IL8 and (h) CCL2 expression. 
Cytokine concentrations were measured by sandwich ELISA, and results were normalised by the total 
DNA content of HUCPV cells and HUVECs. Significance between treatments was tested by ANOVA and 
indicated by an asterisk (α=0.05, *P≤0.05). 
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Table 23 Summary of cytokines in transwell cocultures with Mg degradation products. The “↑, ↓ and ↓↑” 
arrows indicate a significant increase, decrease and reversal from decrease to increase, respectively. 
Field Mechanism Cytokine 
5% O2 20% O2 
D1 D4 D7 D1 D4 D7 
Regulate angiogenesis 
and osteogenesis via 
paracrine signalling 
Pro-angiogenic activity VEGFA ↓ ↑ - - ↑ - 
Endothelial activation and MSC 
migration 
eNOS - - ↑ - ↑ - 
MSC migration, tyrosine kinase 
activity, protein kinase C and 
intracellular calcium signalling 
pathways; angiogenic signals such as 
VEGF 
PDGFaa - - - ↓ ↓ ↑↓ 
VEGF, FGF receptors and following 
pathways 
FGFb ↓ - ↑ ↓ - - 
Cell contact, cell 
morphology, cell stress, 
migration 
Protect MSC or perivascular niche via 
Inhibiting MMPs 
TIMP1 ↓ - - - ↓ - 
Differentiation of MSC, migration, cell-
cell surface adhesion 
MMP13 ↓ - - ↑ ↑ ↑ 
Proliferation, migration and tube-
formation via mediating VEGF and 
MMPs 
IL8 ↓ - - ↑ - ↑ 
Migration of MSC and EC, cell contact CCL2 ↓ - ↑ - - - 
 
5.4.4 HUCPV cell migration and gene regulation  
To measure whether the recruitment of HUCPV cells by HUVECs is influenced by oxygen content and 
Mg degradation products, the migration ability of HUCPV cells was measured via a wound healing assay. 
Therefore, HUCPV cells were cultured on the well bottom, with HUVECs cultured in the inserts to permit 
cytokine sharing without direct cellular contact. The migration of HUCPV cells at 0 and 24 h was 
measured by the wound healing assay in Mg degradation products, with 20 and 5% oxygen 
concentrations. The wound edge at 24 h is indicated in Fig. 24a. An obvious increase in wound closure 
occurred for HUCPV cells under 5% O2 in 4 and 8 mM Mg (Fig. 24b). However, Mg showed no significant 
impact under 20% O2. Black lines were used to indicate the wound edge of HUCPV cells at 24 h. A 
numerical value for wound closure was calculated from the pixel change between 0 and 24 h. The gene 
expression of HUCPV cells and HUVECs is indicated in Tables 24 and 25. Under hypoxia in HUCPV 
cells, ANG, IL8, and VEGFB186 were all increased by 8 mM Mg. Moreover, BMPR1A was upregulated 
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by 2 and 8 mM Mg, and PDGFA was upregulated by 4 mM Mg. Under normoxia, a significant expression 
of ANG was not found, but BMP4 was markedly increased by 2 mM Mg. BMPR1A and FN1 were 
upregulated by up to 8 mM Mg. Expression of FGFb, HIF1A and TIMP1 was increased by 4 and 8 mM 
Mg. COL1A1 and PDGFA were upregulated by 4 mM Mg, while VEGFB186 was increased by 8 mM Mg. 
Under hypoxia in HUVECs, all targets of interest were significantly regulated by Mg, except VEGFB186. 
ANG was increased by 8 mM Mg, but IL8 was decreased by 4 mM Mg. TIMP1 was increased by 2 mM 
Mg while downregulated by 8 mM Mg. The expression of BMPR1A, HIF1A and PDGFA was upregulated 
by up to 8 mM Mg. Under normoxia, ANG, BMPR1A, HIF1A, PDGFA or TIMP1 all showed changes in 
regulation; under hypoxia, no changes were observed for 8 mM Mg. ANG was increased by 2 mM Mg, 
whereas BMPR1A, HIF1A, PDGFA, TIMP1 and VEGFB186 were upregulated by 2 and 4 mM Mg. No 
influence of Mg on IL8 was found under normoxia. 
Fig. 24 Wound healing closure of HUCPV cells in the presence of Mg degradation products under 
hypoxia (5% O2) or normoxia (20% O2). Control and 2, 4, and 8 mM Mg treatments are indicated in white, 
grey, dark grey and black, respectively. (a) Pictures were acquired with an inverted microscope at 0 and 
24 h, and the wound closure area was analysed with ImageJ. Scale bar=500 µm. (b) Values represent 
the no-cell-area difference between 24 and 0 h. Significance between treatments was tested by ANOVA 
and is indicated by an asterisk (α=0.05, *P≤0.05).  
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Table 24 Gene regulation in HUCPV cells during wound healing in transwell coculture. The slash “/” 
means non-significant regulation. Positive and negative numbers mean up- and downregulation, 
respectively. Significance between treatments was tested by ANOVA and is indicated by asterisks 
(α=0.05, *P≤0.05, **P≤0.01 and ***P≤0.001). 
Oxygen 
Mg 
(mM) 
Gene 
ANG BMP4 BMPR1A COL1A1 FGFb FN1 HIF1A IL8 PDGFA TIMP1 VEGFB186 
5% 
2 / / 1.6*** / / / / / / / / 
4 / / / / / / / / 1.3* / / 
8 1.6** / 1.1** / / / / 3.4*** / / 2.1* 
20% 
2 / 4.2** 1.3** / / 1.7* / / / / / 
4 / / 1.5*** 2.1*** 1.6** 2.1** 1.6* / 1.7* 1.6** / 
8 / / 1.3*** / 2.1*** 1.9** 2.0*** 19.0*** / 2.2** 1.9* 
 
Table 25 Gene regulation in HUVECs during wound healing in transwell coculture. The slash “/” means 
non-significant regulation. Positive and negative numbers mean up- and downregulation, respectively. 
The significance between treatments was tested by ANOVA and is indicated by asterisks (α=0.05, 
*P≤0.05, **P≤0.01 and ***P≤0.001). 
Oxygen Mg (mM) 
Gene 
ANG BMPR1A HIF1A IL8 PDGFA TIMP1 VEGFB186 
5% 
2 / 3.7*** 4.0*** / 5.6* 2.5*** / 
4 / 3.2*** 3.2** -1.6* 2.5* / / 
8 2.7* 9.0*** 9.2*** / 3.2* -1.3* / 
20% 
2 3.2* 2.2*** 1.9** / 1.9* 3.0*** 3.1** 
4 / 9.6*** 8.0*** / 4.2* 2.9** 4.2** 
8 / 6.5*** 4.8*** -1.7* 3.8* 5.9*** 3.3** 
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5.5 Magnesium degradation products and hypoxia influenced 
osteogenesis and the cytokine environment after HUCPV/HUVEC 
direct-contact coculture 
5.5.1 Proliferation in direct-contact coculture investigated by DNA content and flow 
cytometry 
To investigate the effects of Mg and hypoxia when influenced by heterotypic cell contact, HUCPV cells 
and HUVECs were seeded as mixtures to achieve direct cellular contact. Under hypoxia (Fig. 25a), the 
total DNA content remained low on day 1, with a significant effect of Mg increasing the concentrations. 
On the next days, even if the effect of Mg was still evident, an increase in the total DNA contents was 
measured (especially on day 4). While analysing cell ratios, the HUCPV cell and HUVEC amounts 
remained constant on day 1. Afterwards, on day 4, the HUCPV cell number strongly increased and 
HUVEC numbers decreased in an Mg-concentration-dependent manner. The same trend, but damped, 
could be observed on day 7. Under normoxia (Fig. 25b), the total DNA content remained rather constant 
over days, and some negative influence of Mg could be measured (e.g., a significant decrease on day 
4 with 8 mM Mg). While analysing the cell ratios, the HUCPV cells also remained relatively constant 
over days. On day 4, compared to the control, increased HUCPV cell numbers could be measured with 
Mg, whereas a decrease was measured with 8 mM Mg on day 7. In contrast, HUVECs dramatically 
decreased in an Mg-concentration-dependent manner on days 4 and 7 (except day 7 with 8 mM Mg).  
Fig. 25 Total DNA content and the ratio in direct-contact coculture. An asterisk indicates significance in 
comparison to the control for the corresponding day. (a) 5% O2 and (b) 20% O2. DNA content was 
investigated by bisbenzimide fluorescence (left abscissa). Cell ratios were calculated by the CD 31 ratio 
and compared to controls; Significance was determined by the ANOVA test (α=0.05, *P≤0.05).  
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5.5.2 Cytokine levels of direct-contact coculture in ELISA tests 
In the direct-contact system, Mg degradation products resulted in a common influence on cell migration, 
angiogenesis and osteogenesis regulators. Under 5% O2, Mg obviously increased the levels of these 
cytokines (Fig. 26). However, under 20% O2, Mg decreased the level of the following migration-related 
cytokines: TIMP1, IL8, CCL2 and MMP13. Additionally, under 20% O2, the VEGFA, PDGFA and FGFb 
regulator were decreased by 4 or 8 mM Mg on day 1 and 7. PDGFA and eNOS were increased under 
20% O2 by 2 or 4 mM Mg. The significant changes in cytokine levels are summarised in Table 26. 
Fig. 26 Cytokine levels in supernatant for up to 7 days in contact or direct coculture. Control and 2, 4, 
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and 8 mM Mg treatments are indicated in white, grey, dark grey and black, respectively. (a) VEGFA, (b) 
eNOS, (c) PDGFA, (d) FGFb, (e) TIMP1, (f) MMP13, (g) IL8 and (h) CCL2 expression levels. Cytokine 
concentrations were measured by sandwich ELISA and results were normalised by the total DNA 
content of HUCPV cells and HUVECs. Significance between treatments was tested by ANOVA and 
indicated by an asterisk (α=0.05, *P≤0.05). 
Table 26 Summary of cytokine expression in direct-contact coculture. The “↑, ↓ and ↓↑” arrows indicate 
a significant increase, decrease and reversal from decrease to increase, respectively. 
Field Mechanism Cytokine 5% O2 20% O2 
Regulate angiogenesis 
and osteogenesis via 
paracrine signalling 
Pro-angiogenic activity VEGFA ↑ ↑ ↑ ↓ - ↓ 
Endothelial activation and MSC migration eNOS ↑ ↑ ↑ ↑ - ↑ 
MSC migration, tyrosine kinase activity, 
protein kinase C and intracellular calcium 
signalling pathways; angiogenic signals such 
as VEGF 
PDGFaa ↑ ↑ - 
↑
↓ 
- ↓ 
VEGF, FGF receptors and following pathways FGFb ↑ ↑ ↑ ↓ - ↓ 
Cell contact, cell 
morphology, cell stress, 
migration 
Protect MSC or perivascular niche via 
Inhibiting MMPs  
TIMP1 ↑ ↑ - ↓ ↓ - 
Differentiation of MSC, migration, cell-cell 
surface adhesion 
MMP13 ↑ ↑ ↑ ↓ ↓ ↓ 
Proliferation, migration and tube-formation 
via mediating VEGF and MMPs 
IL8 - ↑ ↑ ↓ ↓ - 
Migration of MSC and EC, cell contact CCL2 ↑ ↑ ↓ ↓ ↓ ↓ 
 
5.5.3 Osteogenesis investigated by ARS staining and ALP activity 
Since heterotypic cell contact and hypoxia were suggested to enhance osteoblastogenesis, the 
propensity of HUCPV cells to mineralise was evaluated in the non-contact and contact cell culture 
models (osteogenic inducement). The calcium composition and ALP activity are both key indicators of 
osteogenesis maturity. Calcium was determined by the ARS-Ca module. ALP activity was quantified in 
linear relation to the optical density (OD) of p-nitrophenol. The ALP activity (Fig. 27a) and calcium 
deposits (in the form of ARS-stained hydroxyapatite) (Fig. 27b) are key markers for mature osteoblasts. 
Referring to Fig. 27a, compared to HUCPV cells alone or in the transwell coculture, the values of the 
ALP activities were higher in the direct-contact coculture, especially under hypoxia. While Mg 
concentrations had disparate effects in the transwell system (e.g., both increased and decreased with 2 
mM Mg in 5 and 20% O2, respectively), statistical increases were measured with 8 mM in the contact 
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system. Compared to the HUCPV cell monoculture (Fig. 27b), ARS staining was obviously stronger in 
the direct-contact coculture with 8 mM Mg on day 7, especially in hypoxia. 
 
Fig. 27 Mineralisation in HUCPV cell monoculture and transwell and direct-contact coculture on day 7: 
(a) alkaline phosphatase activity and (b) Alizarin Red S staining. Scale bar represents 500 μm. 
Significance was determined by the ANOVA test (α=0.05, *P≤0.05). 
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6 Discussion 
Magnesium biodegradable implants are investigated extensively in regenerative medicine for tissue 
engineering and repairing, which depends on its excellent manufacturing, biocompatibility and 
biodegradability. To develop biodegradable implants, their bioactivity has to be understood. The interplay 
between implants and local in vivo protagonists is complex, but their interaction is also intriguing, 
especially the fate of stromal cells when interacting with environmental factors and implant degradation 
products. The bone fracture environment is controlled and nuanced by many cascades in the intricate 
hierarchical structure of bones. Endothelial and mesenchymal stem cells represent two protagonists in 
bone marrow fostering angiogenesis and osteogenesis. EC-induced angiogenesis can bring nutrients, 
oxygen and bone-forming cells (e.g., MSCs) into the fracture site for healing the host integratively. Bone 
fracture events, such as inflammation, blood clotting and the generation of highly proliferated cell 
populations (such as MSCs), can trigger hypoxic conditions134,135. Hypoxia has been proven to affect 
enzymatic reactions, including mitochondrial respiration and responses involved in tissue development 
and homeostasis136,137. Hypoxia can be dynamic since Mg degradation is oxygen-dependent. Thus, the 
collective effect of Mg and hypoxia was investigated in the MSC-EC monoculture and coculture systems. 
The purity of HUCPV cells and HUVECs was validated by the high positive ratios of CD 31, CD 90 and 
CD 105 and the negative ones of CD 45 and CD 54. The differentiation potential of MSCs was assured 
by their osteogenesis in different osteogenesis media. To refine the cell culture conditions to achieve 
optimal mitochondrial responsiveness, HUCPV cells and HUVECs were documented to generate ATP 
by mitochondrial oxidative phosphorylation. HUVEC proliferation, metabolism, tube formation and 
wound healing were investigated by their monoculture. Moreover, the gene and VEGF mechanism of 
action were studied. Concentrations of 2, 4 and 8 mM Mg ions were applied, considering 1.0 mM Mg to 
be circulating physiologic level, 2 mM Mg to fall at the physiological/pathophysiological transition and 10 
mM Mg to be a high dose for in vitro studies138, 139. 
After a fracture, angiogenesis is one of the early processes of tissue healing and can be influenced by 
its environment (e.g., hypoxia). Angiogenesis defines new blood vessel formation, which is vital to 
Discussion 
 
71 
vascular remodelling, the regeneration of bone fracture and tissue healing. For instance, ECs act in 
crucial roles affecting haemostasis, vascular tone, medial smooth muscle cell growth, immune response, 
coagulation, growth regulation, the modulation of blood flow and the production of extracellular 
matrix131,140,141. To achieve a greater understanding through the entire angiogenesis process, ECs were 
exposed to Mg degradation product in monoculture models mimicking the stages of angiogenesis. The 
migration and morphogenesis abilities, as well as the related gene and cytokine regulation can be 
interpreted in these specific steps. Additionally, ECs located along the entire inner endothelium of a 
vessel interact with MSCs during cellular translocation in blood vessels and the physiological events of 
fracture healing70. Two mechanisms exist for communication between ECs and MSCs: paracrine 
secretion and heterotypic cell contact142. Various paracrine factors, such as cytokines, are produced by 
local cells into the immediate extracellular environment and then influence nearby cells. Heterotypic 
contact defines the interaction between heterogeneous cell populations. For example, cell-cell adhesion 
is led by the surface “cadherin switch”143 and local cytoskeletal reorganisation142. Heterotypic contact 
also mediates serial physiological and pathological cascades, such as the regulation of prostaglandin 
action by OB-EC proximity142 and the E-cadherin/N-cadherin-moderated adhesion between fibroblasts 
and cancer cells that can drive cancer cell invasion144. Moreover, the study of cellular contact is vital for 
improving the biological activity in 3D bioprinting and the stem cell niche environment, where different 
cell populations interact, communicate and undergo storage145.  
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6.1 Magnesium and hypoxia influence the angiogenesis of HUVECs 
Fig. 28 Summary of HUVEC angiogenesis in Mg degradation products (a) and schematic overview of 
HUVEC angiogenesis and effects of Mg and oxygen contents (b). Abbreviations: plasma membrane 
surface potential (ψPM), mitochondrial membrane potential (∆ψm) and 1-methoxy-5-methyl-
phenazinium methyl sulfate (mPMSox) as an oxidative intermediate electron acceptor. 
The basic steps of (sprouting) angiogenesis involve stages such as the enzymatic degradation of the 
capillary basement; endothelial cell proliferation, directed migration, and reorganisation as a tube 
structure (tube formation); vessel fusion and pruning; and pericyte stabilisation146. Hypoxia can be 
induced and influenced by several parameters near the bone fracture and implantation area, therefore, 
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affecting tissue development and homeostasis137. The effect of Mg degradation on the underlying 
molecular events of angiogenesis still needs to be better understood. However, a few studies elaborate 
on the effects of Mg under hypoxic conditions on specific angiogenesis steps. Under normoxia, Mg 
exerts a positive effect on endothelial migration147,70. Even though such stimulation is abolished under 
hypoxia, the decreased endothelial migration could be a target of interest for inhibiting tumours through 
the suppression of microvessel formation, which is vital to tumour metastasis148. Nevertheless, tube 
formation increased with Mg concentration and hypoxia strength, indicates the beneficial role of Mg in 
fracture healing cooperating with its effects on MSC fate, osteogenesis and vascularisation near a 
transplant149.  
The present findings indicate that under hypoxia, Mg extracts do not interfere with angiogenesis but can 
influence angiogenetic factors. During bone healing, hypoxia is temporary but is maintained because 
Mg degradation is oxygen-dependent. Thus, due to the increased proliferation of ECs, increased 
angiogenesis could be expected. However, the antagonist effects of hypoxia and Mg would associate 
to sustain abnormal angiogenesis in pathologic neovascularisation and haemangiomas.  
Increased proliferation was measured with Mg extracts under hypoxia but not under normoxia. A 
previous study reported that MgSO4 (up to 10 mM) can increase the proliferation of endothelial cells137. 
However, such enhanced proliferation was not observed here under normoxia, only under hypoxia, 
which suggests a synergistic effect of hypoxia and HIF expression. Another explanation for this 
discrepancy may be the form of Mg studied. Indeed, different effects of MgCl2 and Mg extracts have 
already been observed during osteogenesis and osteoclastogenesis, suggesting a high complexity for 
the composition and properties of the Mg extract68,150. After ion influx, Mg2+ is an important modulator of 
biological response due to its similarity with other biologically important metal ions (such as Mn2+, Ca2+ 
and Zn+) regarding radius, coordination sphere151 and borderline hard–soft character 152–154. Mg2+ most 
likely displaces other metal ions from functional biomolecules, such as enzyme cofactors or enzymes 
affecting DNA activity155,156. The catalytic steps of DNA topoisomerases and the enzyme–DNA cleavage 
complex both provide basic structural insight regarding the mechanisms by which Mg could influence 
cell proliferation151. Mg reportedly acts as an essential cofactor in nucleotide excision repair, mismatch 
repair, the removal of damaged DNA and the intracellular regulation of the cell cycle and apoptosis157.  
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HUVEC vitality was assessed via two different techniques: (1) by measuring the activity of enzymes or 
oxidoreductases with WST-1 and (2) by determining the mitochondrial membrane potential based on 
R123 staining. Recent research indicates that NADH is responsible for most tetrazolium (WST-1) 
reduction but that the reduction sites are not only in mitochondria but also in the cytoplasm, 
endosome/lysosome membranes and the plasma membrane on the cellular surface157,158. Moreover, 
the membrane potential in respiring mitochondria is not always consistent (as judged by the extent of 
lipophilic ion uptake) with the level of respiration159,160. Therefore, R123 can be applied to obtain a more 
specific mitochondrial level, since R123 is a lipophilic cation whose cellular accumulation within the 
mitochondrial matrix occurs in accordance with the Nernst equation reflecting ΔΨm (aerobic 
respiration)-linked ion potential changes via complex III in the electron transport chain122,133. The 
increased cellular metabolism measured during normoxia and higher Mg concentrations are probably 
due to Mg-induced metabolic adaptations: protein, carbohydrate synthesis151 and the hydrolysis of 
ATPase161,162. Copper (Cu2+) and iron ions (Fe2+/3+) are functional components of respiratory enzyme 
complexes I, III and IV. Ca plays roles in activating NADH dehydrogenase, phosphate carrier and the 
cytochrome oxidase complex163–165. In consequence, the gradient potential can be changed by the 
interference between metal ions. Because of its hydration shell, Mg can be a non-competitive 
antagonism of cations, such as Ca2+, Na+, and K+6. Mg could increase the positively charged inner 
membrane proton gradient, which pumps protons and holds the energy to drive the ATP synthesis by 
F0F1ATPase in the respiratory chains131. Eventually, Mg changes the mitochondrial membrane potential 
according to the electrochemical potential gradient. 
Under normoxia and with Mg extracts, HUVEC migration exhibited a bell-shaped curve. The same 
pattern was observed with VEGFB expression, while VEGFA was constantly downregulated. Under 
hypoxia, migration and the VEGFA levels remained constant. However, VEGFB was upregulated. 
Similarly, under normoxia, tube formation and VEGFA and VEGFB levels were downregulated. 
Nevertheless, under hypoxia, tube formation again remained constant, while VEGFA and VEGFB  were 
upregulated. 
The HIF pathway is proven to be a responder and core regulator of most transcriptional responses and 
other angiogenic factors under hypoxia 166. Our results indicate the regulatory roles of VEGFB during 
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hypoxia and Mg degradation and suggest their cell stage dependence. Compared to VEGFA, the effects 
of VEGFB on angiogenesis remain mainly unexplored. The difference in hypoxia effects on migration 
and tube formation when influenced by Mg degradation relies on HIF downregulation. Studies suggest 
that HIF can upregulate the gene and protein expression of MMPs, TIMPs, NOS, VEGFs and VEGFRs, 
which play major roles in angiogenesis167,168. VEGFRs can be mediated by HIF via the FLT1 promoter 
or through post-translational mechanisms169–172. Hypoxia downregulated the expression of NOS. The 
hypoxia–attenuated, VEGF-stimulated activation of NOS2 has been reported as a consequence of nitric 
oxide release in endothelial migration and proliferation172,173. Our results suggest that the effects of Mg 
and hypoxia can be cell stage dependent. Other reports indicate that the effects of hypoxia may depend 
on cell types174–178.  
Cellular migration begins with detachment from the primary site by reducing adhesion, approaching and 
attaching to the secondary site by motility and increased adhesion179. For example, some cytoskeletal 
proteins can facilitate adhesion but impair chemotaxis though regulating chemotactic signalling or 
hindering the formation of new adhesion to finish the migration. Adhesion often facilitates migration to 
new sites to adapt new tissues by physical links between cell and ECM180. For instance, integrin is a 
known adhesion receptor family. With combinations of the α and β subunits, multiple heterodimers can 
bind to specific ligands of ECMs181,182. Moreover, an adhesion event is also a complex process that 
involves multiple events, such as receptor–ligand binding and the modulation of cytoskeletal 
assembly183. ECM and its degradation by collagenases, such as the activity of MMPs and tissue MMPs 
inhibitors are also involved184,185. ECMs are produced around cells, and the main components include 
glycosaminoglycans, perlecan, aggrecan, fibronectin, laminins, tenascin and collagens186. ECM is a 
highly dynamic structure. This matrix serves diverse functions in the cellular microenvironment but is 
indispensable during the restructuring of tissue architecture, for example, regulating stem cell niches 
and branching morphogenesis187,188. Generally, studies have suggested that ECMs support cellular 
adhesion, migration, proliferation, differentiation, the growth and death of vasculature and bone 
regeneration, which may occur through upregulating molecules such as TGFβ and transmitting 
mechanical support or stresses189–192. ANG can support endothelial adhesion, providing a substratum 
for interacting with ECM molecules and then inducing basement membrane degradation, mainly through 
activating protein kinase B/Akt signalling193–195. MMPs, as the most prominent family of ECM enzymes 
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and their inhibitors, such as  TIMPs, perform vital roles in the turnover of ECMs, for example, collagen 
degradation to allow ductal progression through the basement membrane196. MMPs also cleave many 
growth factors, cytokines and cell adhesion molecules and modulate their functions197–199. Some 
investigation suggests that the sensitivity of MMPs to Mg, which associates with TIMPs, activates NFkB 
and protein tyrosine kinase197–199. Binding to tyrosine kinase receptors, VEGF can induce cell migration 
and new vessel formation as a highly specific mitogen for endothelial cells200. MMPs could also be 
influenced by Mg2+ because MMPs are zinc-dependent endopeptidases in which Mg2+ could interfere 
with Zn2+ because of ion radius similarity201,202. Some reports indicate a role of IL8 in pro-inflammation 
and delayed wound closure203,204. IL8 can be formed in highly inflammatory conditions and produced in 
endothelial cells to attract cells through activating the phosphoinositide 3-kinase-Rac1/RhoA pathway205. 
In contrast, IL8 can promote wound healing and initiate immune responses203,204.  
Mitochondrial potential, as a factor in mitochondrial function, is suggested to relate to the cell migration 
through dynamin-1-like protein (Drp1)-dependent mitochondrial fission or HIF1a accumulation from 
increased ROS206,207. The stimulated metabolism under hypoxia suggests mechanisms by which 
hypoxia can influence the effects of Mg on endothelial metabolism. The elevated mitochondrial 
membrane potential detected in the highly migratory HUVECs also suggests an increased need for 
mitochondrial activity, such as ATP synthesis during migration116. Hypoxia could decrease such 
migration induced by Mg, potentially via suppressing ATPase by Ca2+ release-activated Ca2+ (CRAC) 
channels and AMP-activated protein kinase (AMPK) activation208.  
The present findings also suggest roles for transporters related to the Mg ion. Though the extracellular 
Mg is high, the alteration of intracellular Mg2+ requires Mg2+ transport with ion transporters or channels 
such as TRPM6 and TRPM7209–211. CAPN1 can influence intracellular Mg2+ by decreasing TRPM7 and 
degrading tyrosine phosphatases, such as PTPN23209,212,213. Claudins are transmembrane tight junction 
proteins that are directly responsible for forming ion-selective channels or pores. CLD16 was formerly 
reported to play a critical role in the re-absorption of magnesium214. Oxygen stress can influence the 
downregulation of CAPN1 and CLD16 in HUVECs. Cell morphology is changed in response to adhesion 
and movement during both endothelial migration73 and tube formation215. Reports have suggested that 
the Mg2+ state is dynamically regulated by actin cytoskeleton rearrangement during cell morphology 
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changes74. Mg can enhance migration while decreasing tubule formation by regulating cytoskeleton-
related genes such as ANG, VCAM1, EZR and CD9. These results are consistent with former reports 
that Mg can significantly induce the cytoskeletal reorganisation of HUVECs216,217. Hypoxia can induce 
actin rearrangement and actin stress fibre assembly during cytoskeleton organisation via Rho GTPase 
signalling218 and modify the integration of matrix information218. In endothelial adhesion, growth factors 
and their interaction with adhesion factors can mediate angiogenesis through similar pathways218. 
Adhesion is primarily mediated through integrins binding to the extracellular matrix (ECM), a process 
involving the recognition of specific ECM ligands73. For example, integrin β1 regulates angiogenic cell 
survival and differentiation219,220. Integrins directly interact with growth factor receptors, thereby 
regulating the capacity of integrin–growth factor receptor complexes to propagate downstream 
signalling221. For instance, integrin αvβ3 can cooperate with KDR220. Additionally, angiogenesis can be 
induced by epidermal growth factor (EGF), platelet-derived growth factor (PDGF), insulin, FGFb and 
VEGFs, which requires or relates to the functions of integrin α1β1, α2β1, α5β1, αvβ3 and αvβ5225–228. 
Integrin αvβ3 mediates angiogenesis depending on the ligation state of α5β1 to fibronectin229. VCAM1, 
as an endothelial adhesion receptor, can bind to integrins, which also can be upregulated by Mg229. Mg 
influenced angiogenesis via regulating CD9, which can support VCAM1 function as tetraspanin-enriched 
microdomains229.  
Some clinic and epidemiology reports indicate the potency of Mg in the treatment of tumours because 
of its effects on endothelial proliferation and differentiation. Additional interesting but less efficient facts 
for application, are the pleiotropic and diverging effects on tumour growth230. Under normoxia, Mg 
presents a positive effect on endothelial migration, which accords with a former report147. Even though 
such stimulation was abolished under hypoxia, the decreased endothelial migration could be a valuable 
hint regarding tumour inhibit through the suppression of microvessel formation, which is necessary for 
tumour metastasis. The migration dysfunction induced by Mg could also decrease the secretion of 
angiocrine factors, which normally promote tumour progression187,231. Nevertheless, tube formation 
increased with Mg, and hypoxia strengthened the beneficial role of Mg in fracture healing, cooperating 
with its effects on MSC fate, osteogenesis and vascularisation around a transplant149. Future work will 
focus on developing a more complex in vitro model (e.g., coculture) to further study the interaction 
between MSC activity and angiogenesis.  
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6.2 Magnesium degradation products and hypoxia influence the EC-MSC 
interaction 
 
Fig. 29 Summary of the transwell and direct-contact coculture. Red and green arrow indicate the up- 
and downregulation, respectively. Black arrow represents both up- and downregulation.  
 
After angiogenesis, MSCs can be recruited through blood vessels into fracture sites to support bone 
healing by their proliferation, secretion and differentiation. The bone fracture environment is controlled 
and nuanced by many cascades in the complex hierarchical structure of bones. The recent focus is on 
the cell niche formed by ECs, MSCs, hypoxia and proteins57,58. The communication between MSCs and 
ECs can be classified into an MSC-EC intermediate stage (without contacting), MSC migration step and 
MSC-EC contact stage (Fig. 29) during fracture healing. 
Furthermore, the findings regarding MSC-EC interaction can shed light on the value of Mg in stem cell 
therapy and tissue regeneration. MSCs have been applied in diverse tissue injuries within the field of 
regenerative medicine232 because of their wide resources75; multilineage differentiation potential76 and 
cytokine modulatory effects on the host microenvironment76,233. Implants are crucial carriers to act as 
biotic and abiotic graft scaffolds75.  
At present, the concerns regarding MSC fate most often indicated by many studies are MSC homing80 
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and differentiation81 as well as the regulation of chemokine factors83 and trophic factors234. Mg implants 
are an attractive biomaterial since Mg is a natural mineral component of bones8 and degrades in 
aqueous environments54. Mg has been shown to improve cell motility235 and proliferation236, MSC fate149 
and EC activity40. However, the effects (i.e., molecular mechanisms) of Mg degradation products on 
MSC-EC communication, MSC migration and eventual MSC fate still need to be understood, especially 
when nuanced with dynamic hypoxia and successive heterotypic contacts.  
The present results suggest that Mg could play roles in cellular proliferation, cytokine mechanisms and 
MSC-EC heterotypic contact (Fig. 29). In summary, Mg degradation products are beneficial for the 
microenvironment of MSCs and ECs such as the proliferation of MSCs, increased migration, improved 
expression of cytokines, ECM and HIF-related gene. From comparing the results between transwell 
(non-contact) and direct-contact coculture (contact), heterotypic contact can be crucial for Mg-increased 
osteogenesis.  
Mg decreases MSC proliferation in transwells under hypoxia but increases proliferation in direct-contact 
coculture. Decreased proliferation of ECs is only found in direct-contact coculture. The influence of Mg 
on proliferation could be attributed to the chemical properties of metal ions, which are related to 
molecular or biological activities, as discussed in section 6.1. Mg could potentially influence other metal 
ions, such as Ca and Zn, that occur in metabolic or DNA enzymes152–154. The Mg ion can influence cell 
proliferation via the displacement of these other ions from their biofunctional molecules, thus interfering, 
for example, with enzyme cofactors151,155, DNA topoisomerases and enzyme–DNA cleavage 
complexes151.  
6.2.1 The MSC-EC interaction in the intermediate stage is influenced by Mg and 
hypoxia 
After angiogenesis, MSCs interact with ECs by sharing environmental factors, such as cytokines and 
hypoxia, before MSCs are recruited. The results of the 7-day-transwell cultures suggest that hypoxia 
and normoxia generally affect gene regulation in MSCs and ECs in opposite ways. In the long term, Mg 
degradation products are more beneficial to the cytokine environment under hypoxia than under 
normoxia. The similar influence of ECs on cytokines and EC genes suggests that ECs may act as 
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protagonists towards MSCs when influenced by Mg in the intermediate stage. Moreover, MSC-EC 
transplantation can be a promising therapeutic resource since these cells form the MSC-EC stromal 
niche. The undifferentiated and differentiated cells can exert equal therapeutic effects, such as cytokine 
secretion238. Thus, the cytokine expression during MSC-EC interaction was investigated in transwell 
coculture. Mg is reported to mediate osteogenesis and angiogenesis by regulating VEGFs and their 
subsequent signalling239. Besides the HIF axis, hypoxia is known to couple with VEGFs to improve 
osteogenesis and angiogenesis240. As a core regulator, VEGF can be released from both MSCs and 
ECs, which has been reported to promote revascularisation in injured tissues241. Another important 
group of key regulators preferentially expressed under hypoxia is the family of hypoxia-inducible factors 
(HIFs). Hypoxia triggered HIFs and the subsequent cascades, e.g., the Notch, ANG242 and VEGF 
axes243. ANG can counteract inflammation by reducing IL8 production244. PDGF, TGFβ and NO regulate 
differentiation and the growth of MSCs245. In NO signalling, eNOS plays an important role in the NO 
biosynthesis of vascular endothelium246. Additionally, FGFs play crucial roles in self-renewal247, the 
multiline potential of MSCs248,249 and chemotaxis250. FGFb is also reported to protect MSCs in hypoxia 
conditions251. FGFb and its high-affinity tyrosine kinase FGF receptors have been proven to regulate 
cell survival in angiogenesis and wound healing252. The stimulation of FGFb in angiogenesis depends 
on the expression of the VEGF system, which is induced by Hedgehog activation253. Endothelial 
chemotaxis is triggered and modulated by VEGF and FGFb. CCL2 is critical for migration via 
cytoskeletal rearrangement and the activation of MAP kinase after binding to CCR2185. Additionally, 
CCL2 serves as a potential therapy target since MSCs can influence inflammatory regulation via 
expressing CCL2 to B cells254 and NK cells255. Other important regulators in migration are the matrix 
metalloendopeptidases (MMPs), which breakdown ECM during tissue remodelling256. MMP13 is 
reported to regulate endothelial migration via activating NO signalling257 and mediating adhesion with 
the help of TIMPs258. The degradation and remodelling of MMP13 to ECMs may interact with Mg2+ since 
the endopeptidases are extracellular zinc-dependent enzymes259. The expression of MMPs can be 
directly enhanced by IL8, which depends on CXC chemokine receptor (CXCR) 1/2 expression260. 
PDGFs are mediators in proinflammation, tissue remodelling261, wound healing262,263 migration264 tube 
formation265 and cell proliferation266. PDGFA can mediate EC relaxation via eNOS256. MSCs can secret 
IL8 to promote endothelial proliferation, migration, and tube formation267.  
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6.2.2 MSC migration interaction with ECs is influenced by Mg and hypoxia 
The migration of MSCs can be regulated by many cytokines. For instance, chemotaxis is directed by 
VEGF and FGFb. Haptotaxis is directed towards ligands such as integrins binding to ECMs. The MSC 
migration assays indicate that the influence of Mg is related to hypoxia, with migration generally higher 
under normoxia. The difference between oxygen levels can be ascribed to the influence of genes, such 
as migratory IL8, BMP and ECM pathways268,269. CCL2 is a CC-type chemokine and can be synthesised 
by almost every cell type. Because this chemokine is limited by the distribution of its receptor CCR2 ( in 
monocytes and macrophages, etc.), CCL2 performs inflammatory regulation via triggering intracellular 
Ca2+ mobilisation, cytoskeletal rearrangement and the activation of MAP kinase after binding to CCR2185. 
Additionally, CCL2 proved to be critical for the migration process. Especially, CCL2 plays critical roles in 
the recruitment of monocytes across the vascular endothelium270 in the biomaterial implantation271. 
MMP13, as a protease of MMPs, can breakdown ECMs in physiological and pathological processes that 
include tissue remodelling, arthritis and metastasis256. MMP13 can regulate endothelial migration 
through activating NO signalling257 and mediating adhesion via TIMPs and adhesion molecules258. 
eNOS plays an important role in NO biosynthesis in vascular endothelium246. IL8 can directly enhance 
EC proliferation, survival and MMP expression, which depends on CXCR1/2 expression260. Otherwise, 
IL8 indirectly triggers the angiogenesis of CXCR1/2 lacking ECs272. FGFb and its high-affinity tyrosine 
kinase FGF receptors were proven to regulate cell proliferation, differentiation and survival during 
angiogenesis and wound healing252. The stimulation of FGFb during angiogenesis depends on VEGF 
system expression, which is induced by Hedgehog activation253. TGFβ was shown to regulate the EC 
growth, differentiation and functions. Some data suggest that TGFβ can inhibit the EC growth of different 
cell sources273 via altering the cellular response to growth-stimulatory factors, such as epidermal growth 
factor (EGF), EGF-high-affinity receptors and EGF-induced growth regulatory genes274. However, TGFβ 
was also shown to promote angiogenesis via increasing PDGF and fibronectin as well as partly through 
an autocrine secretion of TGF-α activating PI3K/Akt and p42/p44 MAPK275. TGFβ can regulate EC 
plasticity275 and the EC synthesis of proteases such as MMPs276,277. PDGFs are proinflammatory 
mediators known to contribute to cellular damage and tissue remodelling261. PDGFs and their receptors 
are angiogenic in promoting wound healing 262,263, cell proliferation266, migration264, tube formation265 
and mediating EC relaxation via eNOS256.  
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CCL2/CCR2 also can promote tumour growth with increasing MSC migration278. MSCs can also 
manipulate inflammatory regulation by expressing CCL2 to B cell254 and NK cells255, suggesting that 
CCL2 may serve as a potential target for MSC-based therapy. MMP13 was reported as a marker for the 
prediction and therapy of cancers. The degradation and remodelling roles to ECM of MMP13 can be 
predicted to interact with metal ions such as Mg2+ since its endopeptidases role is extracellular zinc-
dependent259. MMP13 was also proven to be secreted by MSCs to mediate neovascular pathogenesis 
279. The exogenous MMPs can interact with MSCs at the cell surface to influence differentiation, 
angiogenesis, proliferation and migration and regulate the pericellular localisation of MMP activities280. 
The secretion of MMP13 in MSCs can be mediated by TGFβ281 and TIMPs282. MSCs can secret IL8 to 
promote endothelial proliferation, migration and tube formation in cancer-related angiogenesis267. The 
IL8 enhancement of angiogenesis has been reported to relate to VEGFs secretion in part via the 
PI3K/Akt and MAPK/ERK signal transduction pathways241. VEGF, as a crucial regulator in angiogenesis, 
can be released from MSCs and contributes to the therapeutic effects of stem cells by regulating 
angiogenesis and promoting revascularisation in injured tissues241. ANG is an angiogenic growth factor 
that can counteract inflammation via reducing IL8 production244. PDGF, TGF-β, NO and FGF signalling 
have been reported to regulate the differentiation and growth of MSCs245. FGFs play a crucial role in 
self-renewal247, the multiline potential of MSC248,249, the immune response, the inflammatory response 
and the response to wounding and chemotaxis250. A transfection study suggests a role of FGFb in 
protecting MSCs under hypoxia conditions251. The eNOS, which produces perivascular NO via activating 
Notch signalling, is mediated by PDGF283.  
Referring to gene results, MSCs tend to be more regulated by Mg under normoxia. Unlike the results of 
the migration assay, the regulation of the EC gene is more significantly influenced by Mg under hypoxia. 
The Mg influence on MSC migration may depend on mediating MSC genes under normoxia but 
regulating EC involvement under hypoxia, such as increasing cytokine secretion by ECs.  
6.2.3 Magnesium degradation products and hypoxia influence heterotypic EC-MSC 
contact  
After migration or recruitment, MSCs reach the local fracture site. Direct contact between cells reportedly 
triggers signal transduction via widely distributed signalling on the cellular lipid bilayer133. The present 
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comparison between proliferation and mineralisation of transwell and direct-contact cocultures and 
oxygen conditions support the existence of stimulatory roles for heterotypic contact and hypoxia in the 
differentiation of MSCs exposed to Mg degradation products. The improved results of direct contact may 
depend on enhanced MSC proliferation and osteogenesis284,285, which depends on preventing 
apoptosis142. Moreover, cellular contact can improve osteogenesis and angiogenesis241,244,245 by binding 
cytokine receptors on the cellular surface and triggering signalling. MSC migration depends on cytokines 
such as IL8 and CCL2286 as well as MMP activation and reactive oxygen species (ROS)287. The MMP 
activity during migration is strongly related to the cellular surface of MSCs282. The interaction between 
ECs and ECMs can regulate the production of MMPs through matrix-induced signalling, activate 
transcription and result in the formation of multiprotease complexes on the cell surface288. PDGF is 
indicated in the EC–induced recruitment, with heterotypic cell–cell interaction273. FGFs and VEGFs 
perform their functions during cell-cell interaction253 through specific binding to the surface receptors 
equipped with tyrosine kinase activity289. The Notch system is important to cell-cell communication for 
deciding EC fate, angiogenesis290, and osteogenesis291. Notch signalling can be activated by 
perivascular NO283, which is synthesised by eNOS.  
Another hypothesis for the different results between coculture models is other cellular communications, 
such as that based on exosomes or cell transitions. Exosomes are cell-derived vesicles believed to carry 
microRNA (miRNA) and proteins to regulate osteogenesis and angiogenesis by increasing MSC 
proliferation or the delivery of miRNA292. The mobility of exosomes is restricted by the distance between 
neighbouring cells293 and can, therefore, be more efficient in direct-contact coculture. Endothelial-
mesenchymal transition (EndMT) is a cellular interaction during angiogenesis and tissue development 
that can increase MSC proliferation294. VEGFA and FGFb experienced contrary influences in Mg under 
hypoxia in transwells on day 1, and these factors are reported to inhibit EndMT294. The mediator of 
EndMT is concentrated on the cell membrane, similar to lTGFβ and MMPs 295. Thus, the effects of Mg2+ 
on MSC-EC interaction could depend on cellular exosomes or EndMT via cytokine influences or 
signalling related to heterotypic cell contact.  
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7 Conclusion 
Though natural hypoxia is dynamic, a relatively decreased oxygen environment can be maintained 
around the implant because the Mg degradation is oxygen-dependent. During angiogenesis steps, Mg 
extracts did not interfere under hypoxia. An explanatory hypothesis could include the increased 
proliferation of endothelial cells. Additionally, the antagonist effects of hypoxia and Mg would be 
associated to keep angiogenesis unaffected. Note that abnormally increased angiogenesis can also be 
pathological, such as in ocular neovascularisation and haemangiomas. The value of magnesium 
biomaterial for the orthopaedic application is emphasised and could be promising for regenerative 
medicine via improving the stem cell niche and tissue regeneration. Eventually, increased angiogenesis 
and osteogenesis could be expected. Heterotypic contact of stromal MSCs/ECs and hypoxia are 
important elements influencing the effects of Mg. Under hypoxia, Mg can affect proliferation and increase 
migration, angiogenic and other tropic cytokine secretions, as well as gene regulation in the MSC-EC 
cell niche. The effects of hypoxia are associated with MSC migration, VEGFs, ECM and HIF-related 
regulation and cytokines. However, due to limitations of the experiments’ time scale, materials and 
methodology, the effects of Mg and hypoxia may be diminished, and the exact mechanism needs to be 
further clarified. 
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Symbols and abbreviations 
Acronym Definition 
AAS Atomic absorption spectroscopy 
ALP Alkaline phosphatase 
AMPK AMP-activated protein kinase 
ANG Angiogenin 
ANOVA Analysis of variance 
ARS Alizarin Red S 
ATP Adenosine triphosphate 
BMD Bone mineral density 
BMP Bone morphogenetic protein 
BSA Bovine serum albumin 
CRAC Ca2+ release-activated Ca2+ channels 
CRP C-reactive protein 
CSF Colony-stimulating factor 
DNA Deoxyribonucleic acid 
ECAP Equal-channel angular pressing 
ECGM Endothelial cell growth medium 
ECGS Endothelial cell growth supplement 
ECM Extracellular matrix 
EDTA Ethylenediaminetetraacetic acid 
EGF Epidermal growth factor 
ELISA Enzyme-linked immunosorbent assay 
EPAS Endothelial PAS domain-containing protein 
EZR Ezrin 
FBS Foetal bovine serum 
FGF Fibroblast growth factor 
FITC Fluorescein isothiocyanate 
FSC Forward scatter 
GAPDH Glyceraldehyde 3-phosphate dehydrogenase 
GSH Glutathione 
HEPES 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
HIF Hypoxia-inducible factor 
HUCPV Human umbilical cord perivascular 
HUVEC Human umbilical vein endothelial cell 
ICAM Intercellular adhesion molecule 
ICP-MS Inductively coupled plasma mass spectrometry 
ITGAM Integrin alpha M 
JSN Joint space narrowing 
KDR Kinase insert domain receptor 
LDEV Lactate dehydrogenase elevating virus 
MAP Mitogen-activated protein 
MAPK Mitogen-activated protein kinase 
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MCP Monocyte chemoattractant protein 
MEM Minimum essential medium 
MMP Matrix metallopeptidase 
MSC Mesenchymal stem cell 
NADH Nicotinamide adenine dinucleotide (reduced form) 
NMDAR N-methyl-D-aspartate receptor 
NOS Nitric oxide synthases 
ONFH Osteonecrosis of the femoral head 
OPG Osteoprotegerin 
PBS Phosphate-buffered saline 
PCR Polymerase chain reaction 
PDGF Platelet-derived growth factor 
PLA Polylactic acid 
PTH Parathyroid hormone 
RNA Ribonucleic acid 
ROS Reactive oxygen species 
SELE Selectin 
SNK Student-Newman-Keuls 
SSC Side scatter 
TBAR Thiobarbituric acid reactive substances 
TBARS Thiobarbituric acid reactive 
TIMP TIMP metallopeptidase inhibitor 
TLA Thin-layer assay 
TMB Tetramethylbenzidine 
TNF Tumour necrosis factor 
UCB Umbilical cord blood 
USA United States of America 
VCAM Vascular cell adhesion molecule 
VEGF Vascular endothelial growth factor 
VEGFR Vascular endothelial growth factor receptor 
WST-1 Water-soluble tetrazolium salt-1 
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